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Chapter 1. 
REVIEW AND INTRODUCTION 
Introduction. 
The first patient to be treated with insulin was Leonard Thompson, a 14 
year old boy from Toronto, Canada. On January 11, 1922 he received a 
crude extract of an animal pancreas prepared by Banting and Best (1). 
Since then the extraction process from animal pancreas has been greatly 
improved and, as the result of these efforts, preparations with very low 
impurity levels are available since the mid seventies. However the animal 
species has not been changed since 1922 untili recently. First there has 
been a development to use exclusively porcine insulin (PI) and no more 
beef insulin or beef/pork mixtures. This shift has been caused by the 
fact that PI differs from human insulin (HI) in only one aminoacid, 
whereas beef insulin differs in 3 aminoacids, and thus is more immuno­
genic than PI in man. The second important development has been the 
recent introduction of human insulin. Already in 1960, the aminoacids 
sequence of human insulin had been mapped (2). Using these data it was 
possible to make fully synthetic HI in small quantities. However, the 
chemical synthesis of insulin on a commercial scale was not feasible, so 
that other ways to produce HI had to be investigated. Now two different 
processes are available: the transformation of PI to HI (semisynthetic 
HI) and the production of insulin by E. Coli bacteria using the recom­
binant DNA method (biosynthetic HI). These production processes will be 
explained briefly on the following pages. It was of course necessary to 
examine in detail the properties of human insulin and to compare the 
effects of HI with those of PI. This thesis is an attribution to these 
studies. After a summary of the studies by other investigators, it de­
scribes first the method we used to analyse insulin binding antibodies 
and then three clinical studies comparing efficacy and immunogenicity of 
human and porcine insulin. 
Production of semisynthetic human insulin. 
Alanine is the aminoacid in position 30 of the В chain of PI. In HI this 
position is occupied by threonine. The remaining aminoacids sequence of 
10 
Theinsulin molecule 
A-chain 
rs-sn 
ooooooooooooooooooooo 
I I 
s 
s
I 
s 
; 
The conversion of porcine insulin to human insulin 
OOOOOOOOOOOOOOODOOOOOOOOCPOOOO 
| В 30 
В-chain 
S" ® NH2-CH-COOH 
/ " • , 
№ Î » > 5 > : . ; 
CHOH 
СНз 
tí) NH2-CH-COOH 
¿Нз 
Fig. 1. Production process of semsynthetic human insulin. 
The only difference between HI and PI is in the B30 position of the molecule. By replacement of Alanine by 
Threonine in this position, porcine insulin is converted to human insulin. 
the A and В chains of these insulins is identical. In 1966 the first 
attempt was made to transform PI to HI (3). Although the production pro­
cess was not completely succesfull, it was patented anyway. It lasted 
until 1978 before the optimum conditions for this conversion were found 
(4,5). To water, containing a high concentration of a distinct inert 
organic substance and trypsine as the enzyme, porcine insulin and a sur­
plus of threonine ester is added. Under these conditions alanine in the 
B30 position of the PI molecule is replaced by threonine (fig. 1). Using 
this method on PI which is not yet purified chromatographically, and thus 
contains some proinsulin, the loss of about 3% of PI is almost compensat­
ed because trypsin cleaves proinsulin into insulin and C-peptide. After 
this procedure the preparation is purified chromotographically. The 
impurities consisting of trypsin, proinsulin, glucagon and other peptides 
are below 1 part per million in the final preparation. The contamination 
of PI in the semisynthetic HI preparation is less than 0.1«». In 19Θ2 HI 
was produced for the first time in this way on a commercial scale (6,7). 
Production of biosynthetic HI. 
In 1978 Crea et al. (8) published a study on the chemical synthesis of HI 
genes. They prepared separate genes for the aminoacid sequences of the A 
and В chains of human insulin. The DNA sequences were biochemically 
interposed in plasmid rings, circles of DNA in bacteria which are re­
duplicated. By this method considerable amounts of DNA sequences for A 
and В chains were produced. After coupling these sequences to genes of 
galactosidase, Goeddel et al. (9) implanted these new genes into plasmid 
rings of E Coli. By bringing these bacteria in a medium with a high con­
centration of galactose and a low concentration of glucose, they are 
forced to make large quantities of galactosidase and thus also A and В 
chains of insulin. After the bacteria have been loaded with protein the 
membranes are destroyed and the A and В chains in the medium are isolated 
and detached from the galactosidase molecule. The synthesis of A and В 
chains into insulin by Goeddel et al. elded 10-15й of HI (9) because many 
mismatches of A and В chains are possible. In recent production processes 
this yield has been improved up to 50 to 60% (10) and a further improve-
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ment can be expected in the near future. Figure 2 shows the different 
steps of the production process. After the synthesis insulin is purified 
chromatographically. Still remaining impurities must be derived from E 
Coli bacteria. Using a bioassay no endotoxins could be demonstrated in 
Ginea pigs injected with biosynthetic HI (10). With a solid phase radio­
immunoassay no endotoxins could be shown in the insulin preparation above 
a level of 4 parts per million (10). In 10 insulin dependent diabetic 
patients treated with biosynthetic HI for 6 months, no significant 
changes in antibodies against endotoxins could be demonstrated (11). So 
it seems that no significant contamination by E Coli endotoxins is pre­
sent in biosynthetic HI preparations, but this must be confirmed in larg­
er clinical studies. 
New developments are making the production of HI with the recombinant DNA 
method more economic. The first one is that proinsulin can be produced 
now in one step (12) and then can be converted enzymatically to insulin. 
Using this method it is not possible to get mismatches between separate A 
and В chains. The second development is that several companies are pre­
paring a production process in which the polypeptide is not stored in the 
bacteria or other microorganisms, but secreted as an exotoxin, so that 
there is no need to destroy the microorganisms to harvest the insulin. 
Behaviour and effects of HI. 
The efficacy of HI has been reported in several studies. In the next 
paragraphs the different aspects of pharmacokinetics of HI will be dis­
cussed, with special emphasis on the difference between PI and HI for the 
following items: glucose levels, absorption kinetics of subcutaneously 
injected insulin, contraregulation of hypoglycaemias and efficacy in the 
treatment of diabetic ketoacidosis. 
Bloodglucose lowering effects. 
In 1980 Schlüter et al. (13) did not find any difference in the hypo-
glycaemic effect between intravenously administered PI and fully syn-
thetic HI in 12 healthy volunteers. In other studies also no difference 
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was found between the hypoglycaemic effects of short acting PI and semi­
synthetic HI (14,15,16) nor between PI and biosynthetic HI (17,18) after 
subcutaneous injection in small groups of healthy volunteers. In some 
studies, however, a significantly faster decline of blood glucose was 
demonstrated after subcutaneous injection of short acting semisynthetic 
(19) as well as of short acting biosynthetic (20,21) HI. After intra­
venous administration, however, both insulins were equally effective 
(19,21). 
In several clinical studies comparing HI and PI in diabetic patients 
slight differences were found in home-monitored blood glucose using the 
same farmacological formulation and dose. Castillo et al. obtained 
lower blood glucose levels at Θ.30 p.m. in patients treated with two 
injections of hunan Monotard and Actrapid insulin (22). Greene et al. 
found lower blood glucose levels after lunch during HI (23). In a multi­
centre trial Home et al. (24) observed higher prebreakfast glucose levels 
during HI. In other studies, however, no significant differences were 
found (25,26). 
A possible explanation for these differences could be the behaviour of 
insulin after subcutaneous injection. In some studies in healthy volun­
teers the absorption of human insulin, studied by plasma free insulin 
levels after subcutaneous injection of insulins of the same pharmaco­
logical formulation, was slightly faster than the absorption of PI 
(27,28) but several other studies showed no difference (25,29,30,31,32, 
33). 
Since no important differences in blood glucose values were found in the 
clinical studies mentioned, the different absorption of HI and PI from 
subcutaneous tissue, if really existing, is probably not of significant 
clinical importance. 
Counterregulatory responses to hypoglycaemias. 
After i.v. administration of the same amounts of HI and PI in healthy 
volunteers similar decreases of blood glucose were observed in several 
studies (13,31,34,35). Schlüter et al. found identical patterns of coun-
terregulatory hormones after administration of fully synthetic HI and PI 
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(13). However, using the same methods, they observed no increase of 
growth hormone and a smaller reaction of Cortisol after a hypoglycaemia 
induced by biosynthetic HI (31). This was not confirmed by Rosak et al. 
(34). Also after semisynthetic HI these differences were not found (35). 
In clinical studies no differences in frequency of subjective hypo-
glycaemias were found between HI and PI (23,26,36,37,38). So the impres-
sion from these studies is that if this difference in counterregulatory 
effect is real, it has no consequences for the clinical situation. 
Efficacy in the treatment of diabetic ketoacidosis. 
If a difference in efficacy between HI and PI exists, it might be appa-
rent more clearly during the treatment of the most severe acute compli-
cation of diabetes, ketoacidosis. So far, only one study compared the 
efficacy of the two insulins in this acute situation (39) and found no 
difference between HI and PI. The study was not double blind, nor ran-
domized, the treatment schedule varied from one patient to another and 
ketoacids were not measured. Clark et al. (40) compared ketoacid and 
lipid levels in healthy volunteers during infusion of Intralipid and HI 
or PI. They found lower B-hydroxybutyrate levels during HI. From these 
data it is obvious that the question wether HI is more effective than PI 
in the treatment of diabetic ketoacidosis is still open. 
Immunogemcity of HI. 
The purity of insulin preparations has been greatly improved during the 
last decade. Before chromatographical purification, insulin vials con-
tained in addition to insulin also considerable amounts of proinsulin, 
insulin degradation products, glucagon, pancreatic polypeptide and other 
proteins that induce production of Ig-G antibodies. After introduction of 
chromatography as the endstep of the purification process, these impuri-
ties have been reduced to less than a few parts per million. Another 
cause of insulin antibody formation is the fact that HI differs in 3 
aminoacids from beef insulin and in 1 aminoacid from PI (table 1). 
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Table 1. The difference of aminoacid sequence of insulin from 3 species 
Α-chain B-chain 
Species AB AIO B30 
Man Threonine Isoleucine Threonine 
Pig Threonine Isoleucine Alanine 
Cow Alanine Valine Alanine 
Several studies showed marked reduction of insulin antibodies and anti­
bodies to contaminating peptides after changing from conventionally puri­
fied beef/porcine insulin to chromatographically purified PI (41,42,43). 
Higher purified beef insulin also proved to be more immunogenic than 
highly purified PI (37). Since PI is different from HI, it should be more 
immunogenic in man. The expectation was that patients exclusively treated 
with HI would not develop insulin antibodies. However this appeared not 
to be the case. 
Indeed it has been reported, that, compared to patients treated with PI, 
insulin antibodies arise in fewer newly diagnosed diabetic patients and 
in lower titers, when they are treated with HI (44,45). Other investiga­
tors found insulin antibodies in the same percentage of type I diabetic 
patients who had been treated from diagnosis on with HI or PI, but the 
titers were lower in the patients treated with HI (46). In an Italian 
multicentre study no difference in insulin antibody titers was found 
after 6 months of treatment (47). So the immunogenicity of HI may be 
lower than that of PI, but insulin antibodies still arise in patients 
exclusively treated with HI. 
In patients who were treated with mixed beef/pork insulin containing less 
than 50 parts per million of proinsulin, indicating that this insulin is 
not highly purified, insulin antibodies decreased during a follow-up 
period of 6 months with treatment with HI (48). Patients who were treated 
during the same period with purified PI (< 5 parts per million pro­
insulin) showed a decrease of insulin antibodies both on continuation of 
purified porcine as well on transfer to HI. This decrease was not faster 
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nor greater during HI (48). Several investigators (24,37,38) found no 
change in insulin antibodies in double blind cross-over studies after 4 
months of HI in patients who were previously treated with PI. From these 
studies it is not clear whether HI is less immunogenic than PI after more 
than 6 months in patients previously treated with PI, but none of the 3 
studies showed a decrease of antibodies within 4 months. 
So, in summary, insulin antibodies may develop less frequently in newly 
diagnosed diabetic patients treated with HI, compared to patients treated 
with animal insulin. In patients previously treated with PI, insulin 
antibody levels do not decrease within 4 to 6 months. 
The insulin antibodies mentioned above are of the Ig-G type. Ig-E anti-
bodies may also be present. These can induce local or generalised 
allergic reactions to insulin (49). In a group of patients treated with 
monocomponent pork or mixed beef/pork insulin, Ig-E antibody levels did 
not differ significantly from non-diabetic subjects, whereas patients 
treated with conventionally purified insulins and patients with insulin 
allergy had significant higher titers of anti-insulin Ig-E (50). Since HI 
is also highly purified, Ig-E antibodies should not arise more frequently 
in diabetic patients using HI than in non diabetic subjects. However, two 
cases of generalised allergic reactions to HI have been reported. These 
patients were treated previously with mixed beef/pork insulin without 
allergic reactions (51). Several cases were reported in which allergic 
reactions to animal insulin disappeared after transfer to HI (50,51,52, 
53). In most of these cases it took some time before the skin reaction, 
which was still present after the change from animal to HI, disappeared. 
So far, no allergic reaction to insulin has been reported in a patient 
who was treated exclusively with HI. 
Clinical importance of insulin antibodies. 
Berson and Yalow reported in 1964 that very high concentrations of Ig-G 
insulin antibodies can be responsible for insulin resistance, in which 
the daily insulin need exceeds 200 units (54). After the introduction of 
chromatographically purified insulin this resistance has become extremely 
rare. Lower titers of insulin antibodies still arise, and the insulin 
18 
dose is possibly influenced by these low titers (55,56). Vaughan et al. 
(57) found that after withdrawal of insulin in patients with insulin 
antibodies higher levels of free insulin and lower levels of glucose were 
maintained for at least 12 hours as compared to patients without insulin 
antibodies. This buffering effect of insulin antibodies on insulin levels 
was also found during treatment with insulin (55,58). In a study by 
Bistritzer et al., however, insulin antibody binding capacity appeared to 
be negatively correlated with diabetic control (59). Gonen et al. found 
no correlation between insulin antibodies and metabolic control in 100 
diabetic patients (60). So the influence of insulin antibodies on 
metabolic control is not clear. 
The recovery from hypoglycaemias in patients with insulin antibodies is 
slower than in patients without antibodies, due to higher concentrations 
of free insulin after the hypoglycaemia (61,62). In a study using the 
glucose clamp technique serum free insulin concentration was not clearly 
influenced by insulin antibodies, but a high binding capacity of insulin 
antibodies was associated with a longer half live of free insulin (63). 
This implies that insulin levels could be inappropriately high between 
meals. Ludvigsson showed that newly diagnosed type I diabetic children, 
who develop insulin antibodies during treatment, have a shorter remission 
period and a higher insulin requirement than children without insulin 
antibodies (64). Di Mario et al. are the only investigators who suggest 
that immunecomplexes related to insulin antibodies are more frequent in 
patients with microangiopathy (65). If confirmed this observation it 
would mean that insulin antibodies could play a role in the development 
of long term diabetic complications. 
In conclusion, insulin antibodies might have negative effects on the glu-
cose regulation and possibly influence the development of long term com-
plications in diabetic patients. 
Ig-G insulin antibody assays. 
Insulin antibody assays in current use can be divided in three main cate-
gories: solid phase assays, liquid phase assays using one concentration 
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of insulin (one point assays) and liquid phase equilibrium binding 
assays. 
Christiansen developed a method in which the Ig-G antibodies are first 
precipitated, in the presence of an excess of radiolabelled insulin, on 
an anti-Ig-G containing agarose gel and than separated by rocket immuno-
electrophoresis (66). This solid phase assay is widely used, also in most 
of the studies on immunogenicity of semisynthetic HI. The most important 
criticism on this method is that it does not take into account the dis-
sociation between Ig-G and insulin that takes place during the electro-
phoresis. A second, less frequently used, method for the determination of 
anti insulin Ig-G is the ELISA-assay (67). Most other assays are perform-
ed with the insulin antibodies in solution. Since the Ig-G insulin com-
plexes do not precipitate, a separation from free insulin is necessary. 
This separation technique of bound and free insulin can be performed by 
several methods: dextran coated charcoal, cellulose, gel filtration, 
ultracentnfugation, precipitation with salt, ethanol, polyethyleneglycol 
(PEG), protein A or second anti Ig-G antibody. The most widely used 
methods nowadays are PEG precipitation (68,69) and separation by a second 
antibody (70). 
The first and most simple method to quanti tate insulin binding to Ig-G is 
to add a fixed concentration of radiolabelled insulin to plasma and count 
the amount of radioactivity that is precipitated after separation of 
bound and free insulin. The insulin binding capacity can than be express-
ed as percentage bound or amount of insulin bound. This assay method is 
influenced by insulin that is present in the patients plasma. Therefore 
Reeves and Kelly (70) first separated insulin and anti-insulin antibody 
in patients plasma by dissociating the insulin-antibody complex at low pH 
and then absorbing free insulin to dextran coated charcoal. The determi-
nation of the "binding capacity" is than performed in this insulin free 
plasma by adding a fixed amount of a radioactive labelled insulin follow-
ed by precipitation of bound insulin. The radioactivity is then counted 
in the pellet and the amount of bound insulin can be calculated. Since 
binding of a ligand is influenced by binding capacity and binding affini-
ty, it is clear that the total process of binding cannot be described 
completely by a single parameter. If a different insulin concentration is 
used in the assay of Reeves and Kelly (70) mentioned above a different 
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binding capacity will be the result. 
Berson and Yalow (71) demonstrated in 1959 that insulin binding consists 
of an univalent insulin reacting with two distinctly different orders of 
antibody binding sites. This implicates that insulin antibodies can be 
described by four parameters: two binding capacities and two binding 
affinities. From their experimental work it became obvious that insulin 
antibodies consist of a low capacity, high affinity binding site and a 
high capacity, low affinity binding site. Berson and Yalow separated 
bound from free insulin by paper chromatography and they did not separate 
Ig-G from insulin in patient plasma. In more recent studies acidified 
dextran coated charcoal, as described above, was used to separate Ig-G 
and insulin. PEG was used to separate bound from free insulin (68,69). To 
describe the four parameters of insulin antibodies a vast range of 
insulin concentrations must be tested for amount of binding. This makes 
the so called equilibrium binding assays far more laborious than the one 
point assays. Apart from this, Reeves argues that there are probably not 
two but hundreds of different binding sites for insulin in insulin anti-
bodies (72). This might be true, but the work of Berson and Yalow proved 
that the expenental binding results can be explained very well by a 
model of two binding sites and a model in which 3 binding sites were 
assumed did not describe the antibodies better. 
A problem that influences all insulin antibody assays is non specific 
binding of insulin (NSB). For the calculation of specific binding, NSB 
has to be subtracted from total binding. Many factors of the assay method 
influence NSB: removal of insulin from plasma, method of lodination of 
insulin, incubation pH, buffer, separation method, etc. If the NSB would 
also vary between patients the calculation of the binding capacity is 
wrong, since a part of the specific binding is over- or underestimated as 
NSB. Several methods were introduced to make this NSB as low as possible: 
for instance a second antibody and a second tracer to correct for free in 
bound inclusion (70). It is believed by most authors that NSB is only an 
artefact of the assay, but it is unclear so far if it is influenced by 
factors of the individual plasmas. If this would be the case, the results 
of the assay for plasmas containing the same kind and amount of insulin 
antibodies, would differ between plasmas if they are not corrected for 
NSB for each plasma individually. 
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Summary and aim of the studies described in this thesis. 
Two production processes are available to manufacture HI on a commercial 
scale. The blood glucose lowering effects of HI and PI are identical 
after intravenous adinistration. The absorption of subcutaneously inject-
ed HI might be slightly faster than the absorption of PI. In clinical 
studies small differences of home monitored blood glucoses were found 
between PI and HI treated groups. In newly diagnosed type I diabetic 
patients as well as in patients previously treated with animal insulins, 
HI might be less immunogenic than PI. All the above mentioned differences 
between HI and PI are reported by some investigators, but not confirmed 
by others. It is not clear whether HI is more effective than PI in the 
treatment of diabetic ketoacidosis. 
Our aim was to investigate the efficacy and immunogenicity of HI in com-
parison with PI. To study the efficacy we chose to study 3 groups of 
patients: newly diagnosed type I diabetic patients, diabetic patients 
previously treated with animal insulins and patients with diabetic keto-
acidosis. Glucose regulation in the first two groups was assessed by 
several methods, including home blood glucose estimation and HbA1 deter-
mination. To investigate the potency of HI in patients treated with 
animal insulins before, a group of patients was selected who injected 
insulin once a day. By keeping the insulin dose as constant as possible 
in this group of patients, a different behaviour of subcutaneously in-
jected HI as compared with PI should become obvious in a double blind 
cross-over study. The study in patients with a diabetic ketoacidosis was 
designed as a prospective double blind study in which the treatment was 
identical, apart from the double blind adinistration of HI or PI. 
To study the immunogenicity of HI we first developed an insulin antibody 
assay that describes the insulin antibody by two binding sites and that 
corrects for the non-specific-binding for each plasma individually. Using 
this assay insulin antibodies were investigated in newly diagnosed type I 
diabetic patients and in patients previously treated with animal in-
sulins, comparing the immunogenicity of HI and PI treatment. 
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Introduction to Chapter II to V. 
In chapter II the insulin antibody assay is described. The method used 
resembles most the one described by Goldmann and coworkers (6Θ). To 
analyse the data we used a computerprogram describing not only specific 
but also non specific binding per individual plasma. From the study de­
scribed in chapter IV inter- and intrapatient variance of NSB are com­
pared to evaluate the dependence of NSB on individual plasmas. 
To study the efficacy, immunogenicity and influence on residual B-cell 
function of HI, we compared it with PI in the treatment of newly diagnos­
ed insulin dependent diabetic patients. In chapter III a study is de­
scribed that tries to answer these questions. A randomized double blind 
study was designed in which patients received HI or PI and in which nor-
moglycaemia was the aim of the treatment. By comparing insulin dose and 
metabolic control, efficacy of HI and PI could be investigated. The above 
mentioned improved insulin binding antibody assay was used to investigate 
the immunogenicity of the two insulins. Residual B-cell function was 
assessed by a meal test. This stimulation was choosen because it is more 
physiological than estimation of B-cell secretion after injection with 
glucagon. 
A study on efficacy and immunogenicity of HI and PI in diabetic patients 
previously treated with animal insulins, is described in chapter IV. All 
patients were on a once a day insulin regime. The study has a double 
blind, randomized, cross-over design, with a run-in period. During the 
blind periods insulin dose was adjusted as little as possible. This con­
stant dose in patients treated with insulin once a day, provides a better 
opportunity to compare the efficacy of HI and PI than the use of a free 
insulin dose. To assess efficacy and immunogenicity the same methods were 
used as in chapter II. 
A study on potency of HI and PI in the treatment of diabetic ketoacidosis 
is described in chapter V. This study was also prospective and double 
blind. The treatment regime consisted of a fixed protocol of fluid, elec­
trolyte and insulin supplements. During treatment glucose, pH, electro­
lytes, bicarbonate, base excess and ketoacids were measured every hour. 
This design, in /^hich the treatment protocol was the same apart from the 
insulin species use , makes a good comparison of HI and PI possible. 
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After these chapters a summary of the introduction and the four studies 
in the English and Dutch language is provided. 
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CHAPTER 2 
NON-SPECIFIC BINDING OF INSULIN 
IN AN EQUILIBRIUM BINDING ASSAY OF INSULIN ANTIBODIES. 
G.E.M.G. Storms (1), J.A. Lutterman (1), A.H. Ross (2), R. Hermsen (3), 
and G. van Lingen (4). 
(DDepartment of Medicine, Division of General Internal Medicine, 
(2)Department of Medicine, Division of Endocrinology, 
(3)Department of Experimental and Chemical Endocrinology, 
(4)Department of Pharmacology, 
St. Radboud Hospital, Catholic University of Nijmegen, 
Nijmegen, the Netherlands. 
Abstract. 
In liquid phase assays for insulin binding antibodies (IBA), total bind-
ing of insulin is composed of specific and non specific binding (NSB). 
Usually NSB is determined in serum of healthy individuals and then sub-
tracted from total binding of IBA positive serum to obtain specific bind-
ing. This method does not take into account that NSB might vary from 
plasma to plasma. This possibility was investigated by means of a com-
puterised non-linear curve fitting routine for the evaluation of measure-
ment results of an (equilibrium) binding assay for IBA, which yields es-
timates of NSB for each plasma individually. From each of 19 insulin 
treated diabetic patients, 4 blood samples, taken at different points in 
time, were available for IBA and NSB measurement. It was found that be-
tween patient variance of NSB exceeded within patient variance (p < 0.01) 
and, in a number of instances, within patient variance was greater than 
experimental variance. Our results indicate that it is advisable to use 
methods for IBA evaluation that take these NSB variations into account. 
Introduction. 
Various methods have been described for the estimation of specific bind-
ing of insulin to insulin binding antibodies (IBA) appearing in the serum 
of insulin treated diabetic patients (1,2,3,A,5). In all these methods 
some correction is applied for non-specific binding (NSB) which is esti-
mated from the percentage of tracer insulin that is apparently bound by 
the serum of non insulin treated individuals. It has been assumed that 
NSB is purely an assay artefact, reflecting only a certain proportion of 
free insulin that is "misclassified" as bound through the imperfection of 
the free/bound separation step (3,5), and thus is only dependent on assay 
conditions. In this view it is justified to estimate NSB from any serum 
that does not contain IBA. 
Thus the possibility that "free in bound" inclusion may depend on indivi-
dual physicochemical plasma characteristics, is ignored. Furthermore, a 
plasma may contain very low affinity binding sites that cannot be satu-
rated, but nevertheless contribute to total binding, and, if not correct-
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ed for, affect the estimate of specific binding. In either case, esti­
mates of specific binding will be less reliable when using one single NSB 
estimate from non IBA containing plasma for correction. 
In the present study, individual estimates of NSB for different IBA con­
taining plasmas were made in order to investigate NSB variability between 
plasmas from the same patient and between different patients. 
Materials and Methods. 
Patients and plasma collection. 
Serum samples of 19 IBA positive diabetic patients were used for the 
study. In each subject 4 blood samples were collected, each sample with 
an interval of 3 months. Samples were arbitrarily considered as IBA posi­
tive if the percentage of insulin bound in the tube with the lowest insu­
lin concentration was at least twice the percentage of insulin bound in 
the tube with the highest concentration of added insulin (see below). 69 
Plasmas were IBA positive and 7 were negative. Each patient had at least 
2 IBA positive plasmas. Of the IBA positive patients 10 were females and 
9 were males, mean age was 48.3 years (range 17-80), they were on insulin 
therapy for a mean of 5.8 years (range 0.5-31 years). Plasma was imme­
diately separated and stored at -20 0 C . during 3 to 12 months. All plasma 
samples of an individual patient were analysed within one assay run. Four 
runs were performed. 
Insulin binding antibody assay. 
Insulin free IBA containing patient plasma was prepared by vortex mixing 
of 0.5 ml plasma with 0.1 ml 0.1 N HCL and 0.2 ml dextran coated charcoal 
for 5 minutes. After 5 minutes of incubation 0.1 ml 0.1 N NaOH plus 0.1 
ml Veronal Human Serum Albumin (HSA) was added, followed by centrifuga-
tion at 2000 g for 10 minutes. The supernatant, containing insulin free 
IBA, was decanted and used for the further procedure. 
For the determination of insulin binding 50 μΐ of supernatant, contain­
ing 25 μΐ insulin free plasma, was incubated during 3 days at 4 0C. with 
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1 ? 5 
50 μ] of I-insulin (which is equivalent to 40-70 pg), and 50 μΐ stan­
dard insulin solution containing 0, 50, 100, 200, 500, 1000, 2000, 5000, 
10.000, 20.000, 50.000, 100.000 and 200.000 pg of porcine insulin (each 
in duplicate), 100 μΐ gammaglobulin solution (10 g/ 1) and Veronal-HSA up 
to 500 μΐ. After these 3 days 500 μΐ polyethyleneglycol (PEG) 25% (40C.) 
was added and the tube was mixed and centrifuged at 2000 g during 10 
minutes. Then the supernatant was removed and the radioactivity of the 
pellet counted in a gammacounter. 
A computerised non linear curve fitting procedure according to Hermans 
(5) was applied to compute binding parameters from the insulin binding 
data, using a five parameter model for description of binding behaviour. 
In this model two classes of saturable insulin binding sites, with maxi­
mal binding capacities Capi and Cap2 and dissociation constants K1 and 
K2, were assumed. The fifth parameter corresponds to a constant ratio of 
non specifically bound-to-free insulin. It may represent both artefactual 
"free-in-bound" inclusion and actual binding by a third, non saturable 
class of binding sites. These types of binding are indistinguishable and 
mathematically equivalent and thus appear in the equation as a single 
parameter S . Bound insulin concentration (B) is expressed in terms of 
the five parameters and the free insulin concentration (F), according to 
the following equation: 
В = (Cap1xF)/(K1+F) + (Cap2xF)/(K2+F) + (SxF) (1) 
This can be considered as equivalent to models previously presented by 
Feldman (7) and Priore et al. (θ). Bound and free insulin concentrations 
were calculated from the total counts added, the pellet counts, and the 
sum of the amounts of labelled and unlabelled insulin per tube. 
Goodness of fit was expressed as a chi-square value assuming an experi­
mental replicate coefficient of variation of 5&. The results were plotted 
as either a bound versus free curve or a Scatchard type plot (fig. 1A and 
1B). 
Calculation of NSB. 
In the five parameter procedure described above, NSB appears in the form 
of the S parameter. S values were also calculated independently, using 
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Figure IA. Scatchard plot showing specifically bound/free versus specifi­
cally bound insulin and binding parameters m a typical analysis. 
the three highest dose points (tracer + 50.000, 100.000 and 200.000 pg/ 
tube) by means of linear regression analysis according to the equation: 
В = Capi + Cap2 + S'xF (2) 
As can be seen, this is a particular instance of equation (1), which 
holds for values of the free insulin considerably exceeding K1 and K2 
values. This is equivalent to full saturation of the specific binding 
sites. 
Thus, two separate estimates of NSB, S and S' were obtained. 
In plasmas of 20 healthy individuals no difference was found in percen­
tage of bound insulin between the tube with only tracer added and the 
tube with 200.000 pg insulin added, indicating that there was no specific 
binding. For each individual plasma S was assessed by calculating the B/F 
ratio at three insulin concentrations (in duplicate). 
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Figure IB. Plot of bound versus free insulin. The total bound insulin (a) 
can be divided into a saturable specific binding (c) and a non saturable 
non specific binding (b) 
Materials. 
Veronal buffer (0.1 M; pH 8.6) containing 1.25% human serum albumin 
(Veronal-HSA) was used as diluting medium in all experiments. Human serum 
albumin (Albumine Merieux) was purchased from Rhone-Poulenc, Amstelveen, 
Holland. Dextran coated charcoal was prepared according to Dixons 
method (9). Norit GSX was obtained from Hopkins and Williams, Chadwellj 
England and dextran T70 from Pharmacia Upaala, Sweden. Purified porcine 
1 0 h 
insulin (Novo, Bagsvaerd Denmark) was iodinated with I by the chlor-
amine T-method described by Hunter and Greenwood (10). The tracer was pu­
rified by chromatography on Sephadex G25 and G75 columns. Polyethylene-
glycol (PEG) was manufactured by Merck-Schuchardt, Munich, F.R.G. and the 
gammaglobulin was obtained from Boehringwerke, Marburg an der Lahn, 
F.R.G. 
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Further calculations and statistics . 
Of each patient, four plasma samples, which were collected over a 9 
months period, were assayed within one run. In order to estimate within-
run experimental S variance, one plasma was assayed five times. One way 
analysis of variance was applied to 5 values from each assay run for com-
parison of between-patient and within-patient variance, as well as for 
testing within-pat lent variance versus experimental within-run variance. 
Correlation between S and S' was calculated according to Pearson. 
Results. 
In a preliminary experiment in 20 healthy volunteers the intra individual 
variance exceeded the duplicate variance (p < 0.001). 
Figure 1 shows a typical example of a binding analysis. In the second 
figure the plot of bound versus free insulin is shown. The curve can be 
resolved into non specific binding represented by a straight line trough 
the origin, running parallel to the upper part of the fitted line, indi-
Table 1. Intra-assay variation of the binding parameters of an 
equilibrium binding assay of insulin binding antibodies (N=5). 
Parameter S 
Units 
Mean 16.3 
Standard deviation 1.23 
Coefficient of variation (%) 7.4 
K1 = dissociation constant of the high affinity antibodies 
K2 = dissociation constant of the low affinity antibodies 
Cap! = maximal binding capacity of the high affinity antibodies 
Cap2 = maximal binding capacity of the low affinity antibodies 
S = B/F rat " non specifically bound 
Kl 
mmol/1 
0.00857 
0.00335 
39.2 
Capi 
U/l 
0.7609 
0.2481 
32.6 
K2 
mmol/1 
2.63 
0.47 
18.0 
Cap2 
U/l 
12.647 
1.646 
13.0 
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Table 2. Analysis of inter- versus intra-patient variance and intra-
patient versus intra-assay variance of non specific binding of insulin in 
an equilibrium binding assay of insulin binding antibodies in plasmas of 
19 IBA positive patients. 
Run 
number 
1 
2 
3 
4 
Number of 
patients 
5 
7 
5 
2 
Mean 
NSB 
13.14 
22.56 
15.79 
15.42 
AP 
SD 
0.75 
2.58 
3.23 
0.75 
RP 
SD 
2.22 
19.62 
12.94 
12.00 
F-test 
RP versus AP 
ρ < 0.01 
ρ < 0.01 
ρ < 0.01 
ρ < 0.01 
F-test 
AP versus 
NS 
NS 
ρ < 0.05 
NS 
АР-SD = Intra-patient standard deviation 
RP-SD = Inter-patient standard deviation 
AA-SD = Intra-assay standard deviation: this was 1.23 and was analysed in 
run 4 (table I). 
Table 3. Analysis of inter- versus intra-patient variance and intra-
patient versus intra-assay variance of non specific binding of insulin in 
a linear regression analysis of bound versus free insulin in 19 IBA 
positive patients. 
Run Number of Mean 
number patients 
1 5 
2 7 
3 5 
4 2 
NSB 
13.1 
22.6 
18.3 
16.4 
AP 
SD 
0.73 
2.46 
4.26 
1.02 
RP 
SD 
1.77 
16.85 
16.38 
13.16 
F-test 
RP versus AP 
ρ < 0.01 
ρ < 0.01 
ρ < 0.01 
ρ < 0.01 
F-test 
AP versus AA 
NS 
NS 
ρ < 0.05 
NS 
АР-SD = Intra-patient standard deviation 
RP-SD = Inter-patient standard deviation 
AA-SD = Intra-assay standard deviation 
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eating saturation of specific binding, and a composite specific binding 
curve obtained by subtracting non specific binding from the fitted line. 
In each of the 4 runs of the assay inter-patient variance of the S calcu­
lated by the 5 parameter model exceeded intra-patient variance (p < 
0.01). In one of the four runs intra-patient variance exceeded the 
intra-assay variance (p < 0.05) (tables 1 and 2). Calculated by linear 
regression of the highest points of the bound versus free insulin plot 
inter-patient variance of the S exceeded intra-patient variance in each 
of the 4 runs of the assay (p < 0.01) (table 3). 
There was a good correlation between the NSB calculated by the 5 para­
meter model and values calculated by linear regression on the upper 6 
pairs of bound and free insulin. The correlation coefficient was high in 
each of the 4 runs of the assay separately as well as in the 4 runs to­
gether (table 4). The regression coefficient shows a mean overestimation 
of NSB in the linear regression model versus the 5 parameter model, sug­
gesting that specific binding was not completely saturated at the dose of 
50.000 or more pg of insulin. 
There was no correlation between the S and maximal binding capacity of 
the low affinity antibodies (r=+0.21, N.S., N=69) nor between the S and 
the dissociation constant of the low affinity antibodies in the 5 para­
meter model (r=+0.07, N.S., N=69). The possible influence of duration of 
storage was studied by comparing NSB in the 5 model parameter in each 
Table 4. Correlation and regression analysis of NSB values determined by 
the 5 parameter- and linear models. 
Assay run number 1 2 3 4 1+2+3+4 
Corr. coeff. 
Regression coeff. (b) 
Constant factor (a) 
Number of observations 
Ρ value 
(NSB by 5 parameter model) = a + b (NSB by linear regression). 
0.798 
0.815 
0.023 
18 
<0.001 
0.977 
0.851 
0.034 
27 
<0.001 
0.729 
1.018 
0.168 
16 
<0.01 
0.966 
1.194 
-0.014 
8 
«CO.OOI 
0.900 
0.803 
0.039 
69 
•CO.OOI 
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patient in samples obtained with an interval of 6 to 9 months. There were 
no differences detectable in NSB between first (17.4+7,6%; mean±SD) and 
last (17.9+7.1%) frozen plasma (N.S., paired Wilcoxon two sample test). 
Discussion. 
Insulin binding antibodies can be divided into two groups, one character-
ised by a low capacity and high affinity and the other by a high capacity 
and low affinity (1,3,4). In an equilibrium binding assay the Scatchard 
equation is used to calculate these parameters (11). The specific binding 
of IBA to insulin can be found after correction of the total binding for 
NSB. We added the non-specifically bound fraction to the specifically 
bound versus free insulin equation. Thus it was possible to calculate the 
non-specifically bound fraction of insulin for each plasma individually. 
There was no significant correlation between non-specific binding and the 
binding parameters (maximal binding capacity and dissociation constant) 
of the low affinity IBA. This finding renders a poor discrimination be-
tween NSB and low affinity binding site highly unlikely. 
However, the patient dependence of non specific binding could be an arte-
fact of the complexity of the 5 parameter binding model. Therefore we 
calculated NSB also by a simple linear regression of the 6 highest points 
in the bound versus free insulin plot. Using this model, inter-patient 
variance was in each run of the assay also higher than intra-patient 
variance. There was a good correlation between the NSB calculated with 
the 5 parameter model and the linear regression model. The regression 
line shows that there is a mean overestimation of NSB in the linear re-
gression versus the 5 parameter model. This can indicate that even at 
high concentrations of insulin, the insulin antibodies are not always 
completely saturated. 
Usually NSB is calculated from IBA negative plasma (3,5). Such a practice 
implicitly assumes that NSB is an artefact of the assay and not influenc-
ed by properties of the individual plasma, which seems comprehensible 
since NSB is influenced by factors in the assay such as: whether or not 
the insulin is separated from IBA by the acid charcoal method, properties 
of the insulin tracer, the coprecipitated volume in the pellet, 
42 
concentrations of added materials as albumin and gammaglobulin. 
Using the method described above we showed the variability of NSB to be 
larger between than within patients. In one of the four assay runs within 
patient variability even exceeded experimental variability. This was also 
the case in 20 healthy individuals. These facts show that Ν5Θ of insulin 
in an IBA equilibrimi binding assay depends on the properties of plasma 
of the individual subject and possibly it even varies within patients 
during time. 
If NSB is under- or overestimated it has considerable consequences for 
the low affinity binding site. Overestimation results in negative binding 
in the Scatchard analysis and underestimation in a too high maximal bind­
ing capacity of the two binding sites. The problem is reported by Dwenger 
et al. (12) who advise to calculate only the characteristics of the high 
affinity binding site. When binding of insulin to IBA is estimated with 
only one concentration of insulin (5) this problem is not noticed but the 
NSB influences the result anyway. 
In conclusion, non specific binding of insulin in insulin binding anti­
body assays varies between patients and may even vary within one pa­
tient. Therefore it is advisable to take individual NSB into account, 
either by means of a complete parameter fit of binding data that dis­
tinguishes between specific and non specific binding, or by making a 
separate estimate of NSB at saturition concentrations of insulin. 
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CHAPTER 3 
A COMPARISON OF PORCINE AND HUMAN INSULIN 
IN NEWLY DIAGNOSED TYPE I DIABETIC PATIENTS: 
POTENCY, IMMUNOGENICITY AND THE EFFECT ON RESIDUAL B-CELL FUNCTION. 
G.E.M.G. Storms, J.A. Lutterman and A. van 't Laar. 
Division of General Internal Medicin, Department of medicine, 
St. Radboudhospital, Catholic University of Nijmegen, Nijmegen, the 
Netherlands. 
Abstract. 
The efficacy, immunogenicity and influence on residual B-cell function of 
semisynthetic human (HI) and monocomponent porcine insulin (PI) was com-
pared in a double blind, randomized study in 20 newly diagnosed type I 
diabetic patients. 11 Patients were treated with PI and 9 with HI. Data 
were analyzed during a treatment period of 18 months. 7 Patients on PI 
and 3 on HI completed this treatment period. Using two injections a day 
of Actrapid and Monotard, the aim was to reach normoglycaemia. Every 
three months comparisons were made of HbAI, home monitored blood glucose 
measurements (5 times a day) and insulin binding antibodies and a meal 
test was performed to assess residual B-cell function. Initially HbA1 was 
12.6 ± 1.1% in the PI group and 14.7 ± 1.2% in the HI group (p < 0.05). 
After 3 months of treatment this difference had disappeared and the mean 
HbA1 was 8.6%. The mean diurnal blood glucose concentration in both 
groups was not significantly different throughout the study. Also no dif-
ferences could be demonstrated in blood glucose concentration at each 
time point separately with two exceptions: at 6 months the mean 12 a.m. 
blood glucose concentration and at 15 months the mean 7 a.m. blood glu-
cose concentration were significantly higher during PI. The mean variance 
of glucose concentrations between days was lower during HI (p < 0.05). 
The mean of the total daily insulin dose was the same in both groups 
during the study, but at 12 and 18 months fewer patients on PI were 
treated with Monotard insulin in the afternoon. Insulin antibody cha-
racteristics, estimated with an equilibrium binding assay, did not differ 
between HI and PI treated patients. Residual B-cell function assessed by 
measurements of free insulin, proinsulin and C-peptide after a test meal, 
was similar in both groups at any time. It is concluded, that in newly 
diagnosed type I diabetic patients HI is probably as effective and as 
immunogenic as PI. The residual B-cell function is not influenced in a 
different way by HI and PI. 
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Introduction. 
The last few years human insulin (HI) has become available for the treat-
ment of patients with diabetes mellitus. The introduction of the treat-
ment with HI might change the state of two clinical aspects in the treat-
ment of insulin dependent diabetes. The first one is the metabolic con-
trol during treatment with human insulin, compared to animal insulin. In 
several studies the absorption of subcutaneously injected HI proved to be 
faster than the absorption of porcine insulin (PI) (1,2). However, no 
important differences in metabolic control between the treatment with the 
two insulin species were found in clinical studies (3,4,5,6,7). 
The second aspect is the immunogenicity. During the treatment with highly 
purified PI, that differs in aminoacids sequence from human insulin in 
only one aminoacid and therefore possesses a low immunogenicity, insulin 
binding antibodies (IBA) still arise (8,9,10,11). Although the clinical 
importance of IBA is not completely understood, they are incriminated to 
play a role in insulin allergy (12), insulin resistance (13) and early 
decrease or exhaustion of B-cell function in the early phase after the 
diagnosis of insulin dependent diabetes mellitus (14). Since the amino-
acids sequence of synthetic human insulin is the same as endogenous 
insulin in man, it should not be immunogenic at all. However, in several 
studies reported so far, IBA developed in patients treated with HI, but 
in a smaller number of patients and in lower concentrations than in 
patients treated with PI (8,9). 
Several assays are used to measure IBA. The results from these assays are 
totally incomparable since the methods used are quite different. One 
problem all the methods have in common is the measurement of non specific 
binding (NSB) of insulin in the assay. To quantitate the specific binding 
of a given concentration of insulin, this NSB has to be subtracted from 
total binding. Since it is assumed that NSB is an artefact, that depends 
on assay methods only, it is usually calculated from binding of insulin 
in plasma of healthy individuals (15,16,17). To overcome the possible 
influence of individual plasma factors on NSB we developed an equilibrium 
binding assay that characterises IBA by two binding sites, each with its 
own affinity constant and capacity, and by a NSB for each individual 
plasma. 
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We performed a study in newly diagnosed insulin dependent diabetic pa­
tients in which the efficacy, immunogenicity and effect on residual 
B-cell function of monocomponent PI and semisynthetic HI were compared. 
The imunogenicity of the two insulins was assessed by the above mentioned 
IBA assay. Residual B-cell function was measured by a meal test. 
Patients, materials and methods. 
Design of the study. 
Newly diagnosed type I diabetic patients were randomly assigned to double 
blinded HI or PI treatment. After diagnosis or after initial treatment in 
the event of ketoacidosis all were hospitalised for an education course 
of 1 week, in which the theoretical knowlegde about insulin dependent 
diabetes, insulin treatment and diabetic complications was tought. 
Patients were also instructed to inject insulin deep subcutaneously in 
the thigh or in the abdominal wall with a skin fold procedure (1Θ), to 
perform blood glucose measurements at home with Haemoglukotest 20-800 R 
strips and to adjust their insulin dose using these home monitored blood 
glucose concentrations. The aim of the treatment was to achieve normo-
glycaemia. For this purpose all patients used a combination of Monotard 
and Actrapid insulin twice daily. Dependent on the blood sugar regulation 
this schedule could be simplified. After discharge from the hospital the 
patients visited the out-patient clinic once every one to six weeks. 
Before every visit and at least once every three weeks between the visits 
blood glucose measurements at home were performed at θ a.m., 12 a.m., 5 
p.m., 10 p.m. and 3 a.m. A 24 hours telephone service was available for 
problems between the visits. Every three months a meal test was performed 
to assess the B-cell function of the pancreas. For this purpose the 
patients came to the out-patient clinic in a fasting state. Before, 30, 
60 and 120 minutes after their breakfast blood was collected for the 
estimation of glucose, C-peptide, insulin and proinsulin concentrations 
in the plasma. The breakfast consisted of 60 grams of carbohydrate as 
bread plus a glass of milk and remained the same throughout the study. 
HbAI, creatinine and lipid levels were determined every three months and 
IBA every 6 months. 
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Patients. 
20 Patients entered the study. They all had a blood glucose level above 
14 mmol/l and HbAI above 10.0л at diagnosis. The history of weight loss, 
polyuria and other physical symptoms was shorter than 2 months and all 
had ketonuria at diagnosis. 11 Patients were treated with PI and 9 
patients with HI after randomisation. There were no differences between 
the two groups in bloedglucose concentration, age, percentage of ideal 
weight (19), distribution of sex and the presence or absence of keto­
acidosis at diagnosis (table 1). HbA1 at diagnosis was significantly 
higher in the HI treated group (table 1). The follow-up period was 2 to 
36 months. Statistical analysis was performed from 0 to 1Θ months only. 
After this period the number of patients left in the HI group was too 
small for further analysis. 
Table 1: Data at diagnosis of the patients randomized to treatment with 
porcine and human insulin. 
Insulin Porcine Human 
N= 
Female/male 
Ketoacidosis yes/no 
Age in years 
Relative weight (.%) 
Serum glucose (mmol/l) 
Serum glucose range 
НЬА1 (%) 
HbAI range 
11 
4/7 
1/10 
31.9 ± 10.8 
99.2 ± 12.6 
33.4 ± 24.1 
14-99 
12.6 ± 2.2 
10.0-18.0 
9 
4/5 
2/7 
21.9 ± 8.7 
94.2 ± 12.2 
29.0 ± 18.3 
15-78 
14.7 ± 1.2 
13.3-17.0 
* p<0.05 
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Methods. 
Plasma glucose concentrations were measured with an auto-analyser using 
the glucose oxidase method (20). Home blood glucose measurements were 
performed with Haemoglucotest 20-800 R strips (Boehnnger). The strips 
that were used the day before the visit to the out-patient clinic, were 
also measured with a Reflolux meter (Boehnnger) at the out-patient 
clinic (21). HbAI was measured by the Quick Sep Kit after an overnight 
incubation of the erythrocytes :n 0.9°o saline solution (22). Serum 
creatinine was measured wath a countinuous flow analysis with alkaline 
picrate. Cholesterol analysis in serum was performed with the cholesterol 
oxidase PAP method (23) and triglycerides with an improved semi automated 
method for colorimetrie determination (24). The Nakagawa method (25) was 
used to determine free insulin concentrations. Serum C-peptide was ana­
lysed with a radioimmuno assay (26). Promsulin was assayed at the 
laboratory of NOVO Industri, Bagsvaerd, Denmark (27). The IBA assay con­
sisted of an eguilibnum binding analysis, using ^^1-P1 as the tracer 
and PEG as the separation step for bound and free insulin. Concentrations 
of bound and free insulin were calculated for 14 concentrations of total 
insulin. Using these data a computer program calculated binding capacity 
and affinity for two binding sites as well as a non-specific binding for 
each individual plasma. This method is described in detail in chapter 2. 
Statistical analysis and calculations. 
The Wilcoxon two sample test was used to analyse the differences between 
HI and PI treated groups. A two way variance analysis was used to compare 
the mean diurnal, between days and residual variance of home sampled 
blood glucoses during HI and PI treatment. The meal tests were analysed 
using the fasting value and the area under the curve for glucose, 
insulin, C-peptide and promsulin concentrations as well as the in­
crease of these parameters above the fasting-value. Ideal weight was 
expressed as the percentage of the following value: 
1 9104 
women: ideal weight = 3.265 χ height 
men : ideal weight = 3.699 χ height^·900^ 
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These formulas were obtained after loglinear regression of the weight and 
height tables of the Metropolian Life Insurance Company (19) (P < 0.01; 
R = 0.99). 
The analyses were performed from 0 to 18 months. After this period 7 
patients had completed the study in the PI group and 3 in the HI group. 
After the double blind study was ended the patients continued the insulin 
they had before in an open study that is still running. IBA were analysed 
every 6 months. Two patients in the HI group were in the blind study for 
periods between 15 and 18 months. Their IBA values after 18 months were 
analysed while being in the open study. Including these two patients, 7 
patients in the PI group and 5 patients in the HI group completed 18 
months of the study. 
Results. 
Complications. 
During the study no patient suffered from a hypoglycaemia that made a 
medical intervention necessary, nor had any of them a period of ketoaci-
dosis after diagnosis. No allergic reactions to insulin were observed. As 
could be expected no retinopathy nor clinical nephropathy was found in 
any of the patients, as judged by fundoscopy and proteinuria. 
Blood glucose. 
At diagnosis no statistically significant differences in blood glucose 
concentrations could be found between the two groups (Table 1). The blood 
glucose taken at a random time after breakfast during visits at the out-
patient clinic showed a significant difference between HI and PI groups 
only at the first visit (Table 2). The mean home blood glucose concentra-
tion at 7 a.m., 12 a.m., 5 p.m., 10 p.m. and 3 a.m., taken at intervals 
of 3 months on the day before the meal test in the HI and PI groups were 
compared up to a total period of 18 months. Of these 30 Wilcoxon two 
sample tests only 2 reached a significant value. After 6 months of treat-
ment the mean 12 a.m. blood glucose was 5.4 ± 0.8 mmol/1 in the HI group 
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Table 2: Glucose concentration (mmol/1) at the out-patient clinic for 
porcine and human insulin treated patients. 
Insulin porcine N _ human_ N 
Months of treatment 0 
3 
6 
9 
12 
15 
1Θ 
* P<0.05 
7.θ + 2.8 
θ.5 ± 2.2 
9.0 ± 1.9 
Θ.9 ± 2.3 
10.4 t 3.6 
10.4 t 3.6 
11.5 ± 4.7 
10 
10 
9 
7 
7 
7 
7 
* 12.2 ± 4.2 
9.2 ± 1.6 
8.8 ± 1.8 
7.4 + 2.6 
9.9 ± 2.2 
8.0 ± 1.7 
9.3 ± 2.1 
6 
β 
8 
7 
6 
5 
3 
Table 3: Mean ± SO of the home blood glucose (mmol/l) at different time 
points of the study for porcine and human insulin treated patients. 
Insulin porcine N human N 
Months of 
treatment 
0 
3 
6 
9 
12 
15 
18 
10.6 ± 4.7 
7.4 ± 1.5 
8.9 ± 2.5 
7.6 ± 1.4 
8.2 ± 1.2 
8.6 ± 2.0 
9.5 + 2.4 
11 
11 
9 
7 
7 
7 
7 
11.6 ± 5.6 
7.3 + 1.2 
7.1 ± 1.1 
6.6 ± 2.1 
7.8 + 1.9 
6.8 + 0.8 
8.5 ± 2.3 
9 
θ 
β 
7 
6 
5 
3 
(N=9) and 9.7 ± 3.1 mmol/1 in the PI group (N=8) (P<0.05). After 15 
months of treatment the mean 7 a.m. blood glucose was 7.4 ± 1.4 mmol/1 in 
the HI group (N=5) and 10.4 + 2.7 mmol/1 in the PI group (N=7) (P<0.05). 
Since several patients refused to take home blood glucoses at 3 a.m. 
regularly, these figures were not available for all patients. For this 
reason the mean home blood glucose concentration was calculated from the 
other 4 time points. No differences were found between HI and PI groups 
for mean home blood glucose (Table 3). 
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To evaluate the variability of the home blood glucose concentrations, a 
two way variance analysis was performed. For this calculation the glucose 
concentrations at 7 a.m., 12 a.m., 5 p.m. and 10 p.m. after 3, 6, 9, 12 
and 15 months of treatment were used. These values were complete for 7 
patients in the PI treated group and for 5 patients in the HI treated 
group. For each of these patients the diurnal, between days and residual 
variance of the home blood glucose concentrations were calculated. The 
mean between days variance was significantly higher and the residual 
variance tended to be higher during PI (Table 4). 
Table 4: Mean ± SD variance of home blood glucose at 3, 6, 9 12 and 15 
months, compared between human and porcine insulin treated patients. 
Insulin porcine human 
Between days variance 15.0 ± 10.0 * 6.6 ± 2.5 
Within days variance 9.6 ± 8.9 4.5 ± 3.5 
Residual variance 6.1 ± 2.2 о 2.9 ± 2.1 
* p<0.05 
о 0.05<p<0.10 
HbAI. 
At the start (Table 1) and at the first visit to the out-patient clinic 
HbAI was higher in the HI group. At no other time significant differences 
were found between HI and PI treated groups (Fig. 1). During treatment 
the mean HbA1 was B.6%. The upper limit of the HbAI in healthy subjects 
is 7.9% in our laboratory (Mean + 2 SD). 
Insulin dose. 
In the PI group 5 out of 11 patients injected no insulin for 1.9 ± 1.3 
(mean ± SD) months. In the HI group 3 out of 9 patients injected no 
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Figure 1: Mean ± SE HbA1 (Si) in type I diabetic patients treated with 
hunan (·) or porcine (o) insulin. At the start the HbAI concentration was 
significantly higher in the human insulin treated group (* p<0.05). 
insulin for Θ.0 + 6.1 months. No significant differences in the percen­
tage of patients who reached a complete remission nor in the duration of 
the remission were found in the HI and PI treated group. 
Monotard and Actrapid doses were similar in the morning and in the after­
noon for HI and PI groups, with two exceptions. At 12 months the HI group 
(N=6) needed in the afternoon a mean of 4.3 ± 5.1 units of Monotard, 
while all 7 patients of the PI group injected no Monotard insulin in the 
afternoon (P<0.05). At 18 months the HI group (N=3) injected 6.0 ± 6.2 
units of Monotard and the PI group (N=7) injected no Monotard insulin at 
5 p.m. (P<0.05). 
The total insulin dose was not signifficantly different in PI and HI 
groups at any time point (Table 5). 
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Table 6: Mean ± SD fasting creatinine (μιηοΐ/ΐ), cholesterol (mmol/1) and triglyceride (mmol/1) levels 
at different time points of the study for human and porcine insulin treated patients. 
Insulin 
Months of 
treatment 
0 
3 
6 
9 
12 
15 
18 
Great 
Porcine 
75.2+ Θ.7 
73.8+10.7 
71.2±11.B 
70.6±11.5 
68.0+ 7.9 
72.3+12.9 
68.9±11.1 
inine 
Human 
76.U14.4 
73.6+12.9 
73.0± 9.7 
75.0±13.2 
75.7±10.9 
75.0+11.3 
74.3+11.0 
Cholest 
Porcine 
5.3+0.9 
4.7+0.8 
4.9±0.4 
4.9+0.5 
4.9+0.5 
4.8±0.3 
4.7+0.4 * 
eroi 
Human 
4.6+1.4 
4.4±1.0 
4.4±1.2 
4.B+1.3 
4.4+1.2 
4.5±1.3 
3.8±0.6 
Triglyceride 
Porcine 
1.44+0.73 
1.22±0.57 
1.16+0.55 
0.8910.17 
0.9910.25 
0.9710.29 
0.8710.20 
Human 
1.4010.43 
0.8910.56 
1.03+0.60 
1.0710.62 
0.9410.47 
1.04+0.49 
0.53+0.32 
Рог 
11 
11 
9 
7 
7 
7 
7 
N 
. Hu. 
9 
8 
8 
7 
6 
5 
3 
* P<0.05 
Table 5. Mean ± SD daily insulin dose at different time points of the 
study for hunan and porcine insulin treated patients. 
Insulin 
Months of treatment 0 
3 
6 
9 
12 
Porcine 
32.4 ± 16.3 
16.2 ± 13.0 
13.1 ± 5.9 
18.9 + 6.2 
22.9 ± 9.6 
N 
11 
11 
9 
7 
7 
Human 
2Θ.9 ± 15.5 
24.0 ± 17.5 
21.5 ± 18.4 
25.0 ± 20.0 
22.0 ± 14.7 
N 
9 
8 
8 
7 
6 
Creatinine, cholesterol and triglycerides. 
At no time point creatinine or fasting triglyceride levels were different 
in HI and PI treated groups. Cholesterol levels were lower during HI 
after 18 months only (PI: 4.7 ± 0.4 mmol/1, N=7, and HI: 3.8 + 0.6 
mmol/1, N=3, P<0.05) (Table 6). 
B-cell stimulation test (meal test). 
The fasting levels of glucose, free insulin, C-peptide and proinsulin 
were not significantly different in HI and PI groups at any time point 
(Table 7). To evaluate the residual function of В cells of the pancreas, 
the area under the curve untili 2 hours after breakfast was calculated 
for the 4 parameters. At no time point significant differences were found 
between PI and HI groups for these areas under the curve (Fig. 2). To 
assess the reserve capacity of the В cells the area under the curve was 
calculated after subtraction of the fasting value for each of the para­
meters. Also for this reserve capacity no significant differences were 
found between HI and PI groups (Fig. 2). 
Insulin antibodies. 
Insulin antibodies were assayed after 0, 6, 12 and 18 months in 7 pa­
tients in the PI and 5 patients in the HI group as indicated in the 
56 
Table 7: ("fean ± SD levels o f fasting glucose (irmol/ml), C-peptide (fmol/ml) free insul in (т іУ і ) and proinsulin (pnol/ml) at 
d i f ferent tme points of the study for hunan and porcine insul in treated patients. 
Insul in 
rmnths 
of 
treatment 
0 
3 
6 
9 
12 
15 
Glucose 
Porcine 
8.3+2.7 
7.8+1.4 
9.1±1.9 
8.3+1.9 
10.5±3.3 
9.7+1.9 
hunan 
10.8+3.5 
8.3+1.8 
8.7+1.7 
7.6±2.4 
9.8+2.4 
8.0+1.7 
C-peptide 
Porcine 
0.28+0.15 
0.3610.18 
0.4110.19 
0.29+0.12 
0.29+0.13 
0.2110.09 
Hunan 
0.32+0.10 
0.3210.12 
0.3410.20 
0.23+0.10 
0.2410.07 
0.21+0.09 
Insul 
Porcine 
12.214.6 
10.144.1 
1 2 . Ш . 6 
11.0+3.5 
10.6+2.9 
7.0+2.0 
i n 
Kman 
9.2±3.7 
12.714.1 
10.5+4.3 
11.3±2.3 
11.3±1.5 
10.2+3.3 
Proinsulin 
Porcine 
О.ОЗбЮЛМб 
0.07710.057 
0.08410.051 
0.110Ю.116 
0.08310.069 
0.05410.053 
Uman 
0.028+0.020 
0.055Ю.044 
0.057+0.032 
0.054Ю.057 
0.061 Ю.079 
0.03410 .ОВД 
Pbr. 
11 
11 
9 
7 
7 
7 
N 
. rtjn. 
8 
8 
8 
7 
6 
5 
tornai fasting values i n healthy sdDjects: 
C-peptide 0.53 ± 0.16 pnol/l 
Insul in 7.7 ± 4.8 тц/І 
Proinsulin 0.024 + 0.020 avol/l 
AUC (0-2h) free insulin 
( j jU/ml-2h) 
80 
• HI group 
ο Ρ I group 
60 
40 
20 
. / 
К 
Δ AUC (0-2h) free insulin 
32 -. 
24 -
16 
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Figure 2: Mean ± SE area under the curve (AUC) of free insulin, C-peptide 
and proinsulin concentrations after stimulation of their production with 
a meal test in human and porcine insulin treated patients. The tests were 
performed with intervals of 3 months. In the left pannels the AUC is cal­
culated for the concentrations and in the right pannels the AUC curve is 
calculated after subtraction of the premeal value (Δ AUC). No significant 
differences between the human (HI) and porcine (PI) insulin treated group 
were found. 
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Table 8: №эт ± S.D. insul in aitibody paraneters af ter 6, 12 and 18 months o f treatment with porcine and hunan 
insu l in . Included are 7 patients vho were treated with porcine axl 5 patients vto were treated with hunan 
i n s u l i n . 
Time point 
Insulin 
6 tonths 
Ftorcine Hunai 
12 months 
Ftorcine Hunan 
18 months 
Porcine Hunan 
Antibody +/- 3/4 
K1 (rmol/l χ 0.001) 5.66*4.67 
K2 (rmol/l x 0.1) 4.67±3.74 
Capi (U/l χ 0.01 4.20*9.43 
Cap2 (IVI) 0.97±2.39 
3/2 5/2 2/3 4/3 2/3 
1.77±1.48 14.16±8.B0 8.40± 9.18 8.56±1.0B 19.97+3.78 
108.8+178.2 19.63±14.40 10.71+13.61 27.67+39.45 168.8i53.03 
5.91+10.59 6.77+ 8.53 4.30+ 8.93 2.79+ 3.00 5.79+ 8.05 
2.92+5.76 1.30+1.73 0.55± 1Л8 1.10+1.70 3.92+6.17 
K1: Dissociation factor o f high a f f i n i t y antibodies. For calculations only antibocfy posit ive figures are used. 
K2: Dissociation factor of low a f f i n i t y antibodies. For calculation only aitibody positive figures are used. 
Capi: Capacity of hiçh a f f i n i t y antibodies. For calculation antibody posit ive aid negative figures are used. 
Cap2: Capacity of low a f f i n i t y antibodies. For calculation antibody posit ive a r i negative figures are used. 
methods. At the start no specific binding of insulin was found in any of 
the sera. No differences between the two groups were found in non speci­
fic binding at any time. In both groups there was one patient who had 
specific binding for insulin after 6 months, but lost this binding capa­
city at a later time. No significant differences were found between 
binding capacities or affinities for high and low affinity binding sites 
at any time between HI and PI treated groups. No differences were found 
in the ratio binders/non binders at any time point (Table Θ). 
Discussion. 
After the introduction of new production techniques, human insulin has 
become available for the treatment of diabetic patients. In addition to 
its practical and economical benefits, human insulin might also have 
advantages from a clinical point of view. Treatment with this most phys­
iological insulin species might in the first place result in a better 
metabolic control, compared to treatment with animal insulin species. 
To study this, we treated newly diagnosed insulin dependent diabetic 
patients with semisynthetic HI or monocomponent PI and tried to reach the 
best possible metabolic control with two insulin injections a day. The 
total insulin dose was not significantly different in the two groups at 
any point of time. As far as the distribution of the insulin dose during 
the day is concerned, virtually no difference was found between the two 
groups. Many blood glucose concentrations were measured at home during 
the study at fixed time points during the day. Only 2 differences in home 
blood glucose concentrations were found during the whole study. After 6 
months at 12 a.m. and after 15 months at 7 a.m. the blood glucose con­
centration was higher in the PI treated group. Since these are the only 
2, no consistent difference in home blood glucose concentrations between 
the HI and PI treated groups was found. However, the between days 
variance of blood glucose levels was significantly higher during PI 
treatment. This suggests that a more stable metabolic control is possible 
during the treatment with HI. However, the differences between HI and PI 
are that small, that their clinical relevance remains doubtful. 
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Slight but clinically unimportant differences were found in some studies 
(3,4,5), while others found no differences in metabolic control (6,7) 
comparing HI with PI. Our opinion after consideration of the results of 
other and our studies, is that, compared to PI, HI has no important 
advantage for the treatment of insulin dependent diabetic patients. 
The second possible advantage of HI would be an absence of immunogeni-
city. Although insulin binding antibody levels are low during treatment 
with monocomponent PI, they can play a role in allergy (12), and might 
influence insulin pharmacokinetics (28,29) and residual B-cell function 
(14). In 7 patients treated with PI and in 5 patients treated with HI the 
IBA could be analysed after 0, 6, 12 and 18 months of treatment. In con-
trast with results reported before (30) no IBA were found before treat-
ment with insulin. At no time after diagnosis we found significant dif-
ferences in binding parameters between PI and HI treated patients. In 
some other studies in newly diagnosed diabetic patients lovter IBA levels 
were found in HI treated patients (8,9). There might be two reasons for 
this discrepancy. The first is the difference in the IBA assay used. Not 
only the technical part of the assay, but most of the principles on which 
it is based differ. In our assay binding capacity and affinity of 2 dif-
ferent binding sites are estimated with a correction for NSB in each 
individual plasma. In other, less laborious assays, this distinction of 
two binding sites and the individual correction for NSB is not made and 
therefore results are not comparable. Fineberg et al (9), who used an 
assay that also describes capacity and affinity for two binding sites, 
but that not corrects individually for NSB, found also no difference in 
IBA during treatment with HI and PI in newly diagnosed type I diabetic 
patients. A second possible explanation might be a type 2 error in the 
statistical analysis, because of the low number of patients in each 
group. 
In a recent study it is suggested that even low titers of insulin anti-
bodies are associated with progressive loss of B-cell function (14). When 
HI is less immunogenic than PI this should result in a less pronounced 
loss of B-cell function during HI. We tested in all patients residual 
B-cell function with a physiological standardised breakfast test. No dif-
ferences in fasting values nor in rise of C-peptide and free insulin 
levels after breakfast were found, between the groups treated with HI or 
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PI. So, in our study, it was not possible to find a significant differ­
ence in residual B-cell function after treatment up to 18 months with PI 
or HI. After a mean of 6 months of treatment maximal free insulin, 
C-peptide and proinsulin levels were found. After 15 months proinsulin 
levels were decreased as compared to 6 months but were still higher than 
in normal individuals (27). For this high proinsulin levels there are two 
possible explanations. The first one is that proinsulin binds to IBA thus 
prolonging its presence in the blood. However, IBA are relatively con­
stant after 6-12 months while proinsulin concentrations first increase 
and than decrease. Moreover, C-peptide concentrations vary paralell with 
proinsulin levels, indicating a relationship at the level of the B-cell. 
The second explanation is a high output of proinsulin by the B-cell. This 
hypothesis is confirmed by Heding et al (31) who found an abnormally high 
proinsulin/insulin ratio in type I diabetics in the first year after 
diagnosis. 
In conclusion we found that HI in newly diagnosed type I diabetic pa­
tients is as effective and as immunogenic as PI. The residual B-cell 
function is not influenced in a different way by HI and PI. 
References. 
1. Galloway, J.Α., Root, M.A., Bergstrom, R., Spradlin, CT., Howey, 
D.C., Fineberg, S.E., and Jackson, R.L.: Clinical pharmacologic stu­
dies with human insulin (recombinant DNA). Diabetes Саге 19Θ2; 5 
suppl. 2: 13-22. 
2. Sonnenberg, G.E., Kemmer, F.W., Cuppers, H.-J., and Berger, M.: Sub­
cutaneous use of regular human insulin (NOVO): pharmacokinetics and 
continuous insulin infusion therapy. Diabetes Саге 19Θ3: 6 suppl. 1: 
35-9. 
3. Castillo, M., Nemery, Α., Verdín, E., Lefebvre, P.J., and Luykx, 
A.S.: Circadian profiles of blood glucose and plasma free insulin 
during treatment with semisynthetic and biosynthetic human insulin 
and comparison with conventional monocomponent preparations. Eur. J. 
Clin. Pharmacol. 1983; 25: 767-71. 
62 
li. Greene, S.A., Smith, Μ.Α., Cartwnght, В., and Baume, J.D.: Compari­
son of human versus porcine insulin in treatment of diabetes in 
children. Br. Med. J. 19B3; 287: 157B-9. 
5. Home, P.D., Mann, N.P., Hutchison, A.S., Park, R., Walford, S., Moira 
Murphy, and Reeves, W.G.: A fifteen-month double-blind cross-over 
study of the efficacy and antigenicity of human and pork insulins. 
Diabet. Med. 1984; 1: 93-8. 
6. Sestoft, L., Volund, Aa., Gammeltoft, S., Birch, K., and Hildebrandt, 
P.: The biological properties of human insulin. Acta Med. Scand. 
1982; 212: 21-28. 
7. Sonnenberg, G.E., Chantelau, E., Sundermann, S., and Berger, M.: 
Human and porcine regular insulins are equally effective in sub­
cutaneous replacement therapy. Diabetes 1982; 31: 6D0-2. 
8. Schernthaner, G., Borkenstein, M., Fink, M., Mayr, W.R., Menel, J., 
and Schober, E.: Immunogenicity of human insulin (NOVO) or pork mono­
component insulin in HLA-DR-typed insulin-dependent diabetic indivi­
duals. Diabetes Care 1983; 6 suppl. 1: 43-8. 
9. Fineberg, S.E., Galloway, J.Α., Fineberg, N.S., Rathbun, M.J., and 
Hufferd, 5.: Immunogemcity of recombinant DNA human insulin. Diabe-
tologia 1983; 25: 465-9. 
10. Heding, L.G., Marshall, L.O., Persson, В., Dahlquist, G., Tholme, В., 
Lindgren, F., Akerblom, Η.К., Rilva, Α., Knip, M., Ludvjgsson, J., 
Stenhamar, L., Stromberg, L., Sovik, 0., Baevre, H., Wefnng, K., 
Vidnes, J., Kjaergard, J.J., Bro, P., and Kaad, P.H.: Immunogemcity 
of monocomponent human and porcine insulin in newly diagnosed type 1 
(insulin dependent) diabetic children. Diabetologia 1984; 27: 96-8. 
11. lavioli, M., Di Mario, U., Coronel, G.Α., Dawud, A.M., Arduim, P., 
and Leonardi, M.: Semisynthetic human insulin: biologic and immuno­
logic activiti in newly treated diabetic subjects during a six-month 
follow-up. Diabetes Care 1984; 7: 128-31. 
12. Berke, L., Owen, J.Α., Atkinson, R.L.: Allergies to human insulin. 
Diabetes Care 1984; 7: 402. 
13. Berson, S.A., and Yalow, R.S.: The present status of insulin antago­
nist in plasma. Diabetes 1964; 13: 247-59. 
14. Ludvigsson, J.: Insulin antibodies in diabetic children treated with 
63 
monocomponent porcine insulin from the onset: relationship to B-cell 
function and partial remission. Diabetologia 1984; 26: 13Θ- 41. 
15. Goldman, J., Baldwin, D., Pugh, W., and Rubenstein, A.H.: Equilibrium 
binding assays and kinetic characterisation of insulin antibodies. 
Diabetes 1978; 27: 653-60. 
16. Gerbitz, K.D., and Kemmler, W: Method for rapid quantification and 
characterisation of insulin antibodies. Clin. Chem. 1978; 24/6: 
890-4. 
17. Reeves, W.G., and Kelly, W.: An immunochemical method for the quanti­
fication of insulin antibodies. J. Immunol. Meth. 1980; 34: 329-38. 
18. Michels, R.P.J.: Praktische problemen rondom het inspuiten van 
insuline. Ned. Tijdschr. Geneeskd. 1983; 127: 1974-8. 
19. Statist. Bull. Metrop. Life Insur. Co. 1959: 40. 
20. Trinder, P.: Continuous flow adaption of the 60D-PAP method. Ann. 
Biochem. 1969; 6: 24. 
21. De Nobel, E.: Preservation of blood-glucose strips. The Lancet 1979; 
ii: 1365-6. 
22. Abraham, E.C., Huff, T.A., Cope, N.D., Wilson, J.В., Bransome, E.D., 
and Huisman, T.H.J. : Determination of glucosylated haemoglobulin 
(HbAI) with a new micro column procedure. Diabetes 1978; 27 :931-7. 
23. Tarbutton, P.N., and Gunter, CR.: Enzymatic determination of total 
cholesterol in serum. Clin. Chem. 1974; 20: 724-5. 
24. Demacker, P.N.M., van Oppenraay, J.B.H.A., Baadenhuysen, H., and 
Jansen, A.P.: An improved sémi automated method for the colorimetrie 
determination of triglycerides in serum. Clin. Chim. Acta 1975; 64: 
45-50. 
25. Nakagawa, S., Nakayama H., Sasaki, T., Yochino, K., Yu, Y.Y., 
Shinozaki, K., Aoki, S., and Hashimo, K.: A simple method for the de-
termination of serum free insulin levels in insulin treated pa-
tients. Diabetes 1973; 22: 590-600. 
26. Lutterman, J.Α., Benraad, T.J., and van 't Laar, Α.: The relationship 
between residual insulin secretion and metabolic stability in type I 
(insulin dependent) diabetes. Diabetologia 1981; 21: 99-102. 
27. Heding, L.G., and Kasperska-Czyzykowa, T.: C-peptide and proinsulin 
after oral glucose. Acta Med. Scand. 1980; suppl. 639: 33-6. 
64 
28. Keilacker, H., Rjasanowski, I., Ziegler, M., Michaelis, D., 
Woltanski, К.-P., and Besch, W.: Insulin antibodies in juvenile dia­
betes mellitus. Correlations to diabetic stability, insulin require­
ment and duration of insulin treatment. Horm. Metabol. Res. 1982; 14: 
227-32. 
29. Gray, R.S., Borsey, D.Q., Kurz, Α., Rainbow, S., Smith, A.F., Melton, 
R.A., Duncan, L.J.P., and Clarke, B.F.: Relationship of glycosylated 
haemoglobin to C-peptide secretory status and antibody binding of 
insulin in insulin-dependent diabetes. Horm. Metabol. Res. 1981; 13: 
599-603. 
30. Palmer, J.P., Asplin, СМ., demons, P., Lyen, K., Tatpati, 0., 
Raghu, P.K., and Raquette, T.L.: Insulin antibodies in insulin depen­
dent diabetics before insulin treatment. Science 1983; 222: 1337-9. 
31. Heding, L.G.: Specific and direct radioimmuno assay for human pro-
insulin in serum. Diabetologia 1977; 467-74. 
65 

CHAPTER 4 
EFFICACY AND IMMUNOGENICITY OF HUMAN AND MONOCOMPONENT PORCINE INSULIN: 
A RANDOMIZED DOUBLE BLIND STUDY 
IN DIABETIC PATIENTS PREVIOUSLY TREATED WITH INSULIN. 
G.E.M.G. Storms, J.A. Lutterman and A. van 't Laar 
Division of General Internal Medicine, Department of Medicine, St. 
Radboud Hospital, University of Nijmegen, Nijmegen, The Netherlands. 
Abstract. 
In 32 insulin treated diabetic patients the efficacy and immunogenicity 
of monocomponent porcine (PI) and semisynthetic human (HI) insulin were 
compared in a randomized, double blind, cross-over study. After a run-in 
period of 3 months the patients were randomized into group I (N=19) 
treated with porcine insulin first and then with human insulin for pe-
riods of 3 months and group II (N=13) treated with human insulin first 
and porcine insulin subsequently. The insulin dose was kept as constant 
as possible and differed not between the two groups. During HI in group 
II there was a significant increase of HbA1 (11.211.3 to 11.611.4Ä, ρ < 
0.05). The mean blood glucose at 12 a.m. during HI in group I exceeded 
the one during PI (15.0+6.3 (HI) and 12.714.6 mmol/1 (PI), ρ < 0.05). For 
both groups together the diurnal variance of blood glucoses during PI 
exceeded the one during HI (p < 0.05). No other differences were found. 
Insulin antibodies were determined by an equilibrium binding assay. 19 
Patients were IBA positive. During HI the low affinity binding site capa­
city decreased for group I and II together (p < 0.05) and the capacity of 
both binding sites decreased in group II (p < 0.05). We conclude that 
there are small differences in the efficacy of human and porcine insulin 
that are of no clinical importance and that after changing from porcine 
to human insulin, insulin antibodies decrease within 3 months. 
Introduction. 
The last few years human insulin (HI) has been available for the treat­
ment of diabetic patients. It differs from porcine insulin (PI) in only 
one aminoacid. Human insulin can be produced by the recombinant DNA 
method (Biosynthetic Human Insulin) (1) and by enzymatic replacement of 
alanine by threonine in the B30 position of the porcine insulin molecule 
(Semisynthetic Human Insulin) (2). 
So far no clinically important differences in efficacy have been found 
between highly purified porcine and human insulin (3-7). According to 
some studies (6,7,8) hinan insulin is absorbed slightly faster from sub­
cutaneous tissue than porcine insulin, but in other studies (9,10) no 
difference was found. 
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A theoretical advantage of human insulin could be its absent or low immu-
nogenicity in diabetic patients, although the importance of insulin anti­
bodies from a clinical point of view is not clear, apart from rare cases 
of insulin resistance and insulin allergy. Since beef insulin is more 
immunogenic than porcine insulin (11,12), a comparison between human and 
porcine insulin seems the next logical step. It has been shown in newly 
diagnosed type I diabetic patients, treated with human insulin, that in­
sulin antibodies still arise but in a smaller percentage of patients and 
in lower titers (13,14,15). In studies in patients previously treated 
with animal insulins, HI caused a decrease of insulin antibodies in some 
studies (13), but in others no change was found (16,17). The studies on 
immunogenicity of HI are difficult to compare because of the different 
assays for insulin antibodies. 
We studied the efficacy and immunogenicity of HI. A double blind ran­
domized cross-over study was designed, in which semisynthetic HI and 
monocomponent PI were compared. The study was performed in patients pre­
viously treated with insulin. We studied insulin binding antibodies more 
extensively than was done in most studies so far, and we used an assay in 
which non specific binding is accounted for in a new manner. 
Materials and methods. 
Design of the study. 
In a run-in period of 3 months, the selected patients were treated with 
PI. During this period the treatment was adjusted, the diet was revised 
and altered if necessary, injection technique was inspected and education 
was given if necessary. Next the patients were randomized into two groups 
and the study was continued in a double blind way for patient and physi­
cian as far as the type of insulin was concerned. In the first group PI 
was continued for another 3 months and than replaced by HI during a 
period of 3 months (group I). In the second group the patients received 
first HI and then PI (group II). 
The insulins 'sed in this study were monocomponent Actrapid and Monotard 
insulin, both μοι .ine and human. Only 3 patients used Actrapid insulin, 2 
in groi I and 1 i.n group II. 
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The insulin dose during the blind periods was essentially not changed. 
Only subjective hypoglycaemias and blood sugars below 3.0 mmol/1 or 
hyperglycaemias above 20.0 mmol/1, that could not be explained by other 
reasons than insulin dose, caused dose adjustments. During the study all 
patients visited the out-patient clinic once in every 3 weeks in the mor-
ning after breakfast where all were seen by the same physician. 
Patients. 
43 insulin dependant diabetic patients, willing to cooperate and using 
insulin for at least half a year, were selected. They all injected insu-
lin once a day (long acting with or without short acting insulin) for 
various reasons, for instance high age or refusal to use more than one 
injection. None of them had serious diabetic complications. All patients 
gave informed consent and the protocol of the study was approved by the 
ethical committee of our hospital. 
37 Patients reached the end of the run in period. Six patients dropped 
out during the run-in period because of personal reasons or medical 
reasons not connected with insulin use. During the blind periods there 
were 5 more drop-outs: 2 for personal reasons, 1 because of a progres-
sively increasing insulin need and 2 because of serious hypoglycaemias, 
both within 2 weeks after the start of HI. 32 Patients completed the 
study, 19 in group I and 13 in group II (figure 1). 
The basal data of the patients who completed the study are shown in table 
1. As to these data there were no significant differences between the two 
groups. 
Parameters of diabetes control. 
The day before each visit to the out-patient clinic the patients collect-
ed at home their 24 hours urine divided in 4 portions (8-12a.m., 12a.m.-
6p.m., 6-11p.m., 11 p.m.-8a.m.). Blood glucose monitoring was performed 
with Reflotest (Boehringer) strips at 7 a.m., 12 a.m., 5 p.m., 11 p.m. 
and 3 a.m. The next day these strips were measured (Reflomat, Boeh-
ringer) at the out-patient clinic (18). The urine was tested for glucose 
and ketone bodies by Gluketur strips (Boehringer). If the test was posi-
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Figure 1: Design of the study and numbers of patients. 
Ρ indicates treatment with PI and Η treatment with HI. For the reason why 
patients dropped out of the study see text. 
Table 1: Data at the start of the study of the patients who completed the 
study. 
Total group 
N 32 
16/16 
18/14 
yr 48 (18-80) 
yr 12 (0.5-39) 
yr 8.2 (0.5-39) 
women/man* 
type I/II sec. failure** 
mean age (range) 
duration diab.-mellitus 
duration insulin-therapy 
% of ideal body weight 
length 
Group I 
19 
11/8 
11/8 
50.0+16.9 
12.3110.9 
8.2+11.1 
109+13 
169+8 
Group II 
13 
5/8 
7/6 
45.4±19.7 
11.2+10.7 
8.2+10.5 
102+13 
173±11 
* A chi square test was used to compare sex and type I/II diabetics. 
For the other parameters the student Τ test was applied. No signifi­
cant differences were found. 
** Secondary failure in type II diabetic patients means that it was 
necessary to transfer patients from tablets to insulin. 
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tive for glucose a quantitative measurement was performed. Plasma gluco­
se, HBA1 and bodyweight were measured at each visit to the out-patient 
clinic. The patients were asked for the number of subjective hypoglycae-
mias, causing them to take carbohydrates, that they had experienced be­
tween the two visits. At the start of the study and at the end of each 
period of 3 months insulin antibodies were determined. 
Methods. 
Ideal weight was calculated by a formula obtained after loglinear re­
gression from the tables for medium frame size of the Metropolitan Life 
Insurance Company (19). A good correlation was found for the line fitted 
in this way both for women and men (R = 0.99; Ρ < 0.01). The formulas are 
as follows: 
Women : ideal weight = 3.265 χ height"! «9104 
Men : ideal weight = 3.699 χ height 1· 9 0 0 3 
When the height is expressed in centimeters, the ideal weight (IW) is 
expressed in grams. The percentage deviation of the ideal weight (DIW) is 
calculated as: DIW = (weight - IW) χ 100 / (IW). 
Glucose in plasma and urine was measured with an autoanalyser using the 
glucose oxidase method (20). HbA1 was measured after an overnight incuba­
tion of the erytrocytes in 0.9% saline by the Quick-Sep Kit (21). Insulin 
binding antibodies (IBA) were analysed by an equilibrium binding assay, 
characterising the antibodies by two specific binding sites, each one 
having its own affinity and capacity. Insulin and IBA were separated by 
the method described by Dixon (22). To the insulin free plasma a 
125j
oc
jj
ne
 porcine insulin tracer and increasing amounts of non labelled 
porcine insulin were added. After an incubation of 3 days at 4 0C, bound 
insulin was precipitated by polyethyleneglycol 25% (PEG). The pellet was 
than counted in a gamma counter. Using these counts pairs of bound and 
free insulin were calculated and than fitted in a non linear computer 
program by iteration using the following formula: 
В = (Capi χ F)/(K1 + F) + (Cap2 χ F)/(K2 + F) + S χ F 
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В = concentration of bound insulin. 
F = concentration of free insulin. 
Capi and Cap 2 = maximal binding capacity of first and second binding 
site of insulin antibodies. 
K1 and K2 = dissociation constant of first and second binding site of 
insulin antibodies. 
S = ratio B/F non specifically bound. 
For each plasma containing IBA these parameters were calculated. New in 
this assay is the assessment of non specific binding of insulin per indi­
vidual plasma. 
Changes of HbAI, insulin dose and IBA were tested with a paired Wilcoxon 
test comparing parameters at the start and the end of the periods. Unless 
mentioned otherwise group I and group II were analysed separately. This 
was done because the HI period always followed a PI period, but the PI 
period did not always follow a HI period (fig.1). Moreover, the groups 
did not comprise the same number of patients. Variability of home moni­
tored blood glucose was analysed using a two way variance analysis. The 
mean of the parameters obtained at all visits during a period was calcu­
lated. The mean values of HI and PI periods were compared by a paired 
Wilcoxon two sample test. The results are expressed as mean ± SD. If 
other tests were used this is mentioned. 
Results. 
Insulin dose. 
The mean insulin dose was the same at the start and at the end of HI and 
PI periods (table 2). During ΘΘ visits to the out-patient clinic in group 
I the insulin dose was adjusted 12 times in a total of 7 patients of 
group I during PI. The mean of the dose changes was +0.2+4.6 units of 
insulin. During 86 visits in group I the dose was adjusted 13 times in a 
total of θ patients during HI. The mean of the dose changes was +1.1±3.6 
units of insulin. There was no significant difference between HI and PI 
periods in dose adjustment in group I. During 55 visits in group II the 
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dose was adjusted 5 times in a total of 3 patients during PI. The mean of 
the dose changes was +0.4±4.1 units of insulin. During 66 visits in group 
II the dose was adjusted 6 times in a total of 3 patients during HI. The 
mean of the dose changes was 0.0+4.4 units of insulin. There was no sig­
nificant difference in dose adjustments between HI and PI periods in 
group II. 
Table 2: Insulin dose (U/24 hours) at the end of each period. 
run-in period period 1 period 2 
Group I (N=19) 30.1+11.6 (PI) 29.7+10.4 (PI) 29.5±10.7 (HI) 
Group II (N=13) 28.9± 9.7 (PI) 30.3+12.5 (HI) 30.2±12.1 (PI) 
(PI) means treatment with porcine insulin. 
(HI) means treatment with human insulin. 
No significant differences were found between end of period 1 and 2 in 
both groups. 
Glucosuria and ketonuria. 
The mean glucosuria during 24 hours was calculated for each patient 
individually in HI and PI periods. As well in group I (PI period 32.θ and 
HI period 40.8 g/24hours) as in group II (HI period 64.5 and PI period 
55.2 g/24 hours) the mean glucosuria during HI exceeded the mean glucos­
uria during PI. These differences however were not statistically signi­
ficant. When glucosuria in the four portions of the day was analysed it 
appeared to be significantly higher from 12 a.m. to 6 p.m. during HI in 
both groups. In group I glucosuria was also higher during HI from 8 a.m. 
to 12 a.m. (table 3). 
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Table 3: Mean glucosuria (= S.D.) in grams during HI and PI, tested for 
the different parts of the day and for 24 hours. 
GROUP I GROUP II 
PERIOD 
Θ-12 am 
12am-6pm 
6-1Opm 
10pm-Bam 
24 hours 
HI 
10.4+ 7.5 
9.8± 9.7 
9.U10.3 
11.5+ 7.0 
40.8+28.8 
PI 
* 6.9+ 5.9 
» 7.3+ 8.9 
8.5+ 8.3 
9.8+ 7.3 
32.8+25.0 
HI 
15.9+ 6.6 
PI 
15.8+ 9.0 
19.8+12.6 * 11.6+ 5.1 
14.9+ 8.7 
13.6+ 9.5 
64.5+29.6 
11.2± 7.2 
16.1+13.9 
55.2±25.6 
* ρ < 0.05 
Ketonuria was very infrequent. In group I ketonuria was found in 4 out of 
352 urine samples during PI and 8 out of 340 urine samples during HI. In 
group II ketonuria was found in 1 out of 220 urine samples during PI and 
0 out of 256 urine samples during HI. The differences between HI and PI 
periods were not statistically significant. 
Blood glucose. 
Each patient was asked to perform at home a blood glucose test 5 times a 
day. The range of the Reflometer is between 3 and 20 mmol/1. Since there 
were figures beyond this range, differences between HI and PI periods 
were analysed using a sign test. For the calculation of the median blood 
glucose values in the individual patients, concentrations below 3.0 
mmol/1 were considered to be 3.0 mmol/1 and above 20.0 mmol/1 were cal­
culated as 30.0 mmol/1 arbitrary. To arive at the mean value of the group 
the individual median values were avaraged. No significant differences in 
mean blood glucose values between HI and PI periods were found at 8 a.m., 
5 p.m., 11 p.m. and 3 a.m. The mean glucose at 12 a.m. was 15.0±6.3 
mmol/1 during HI and 12.7±4, 6 mmol/1 during PI in group I (P < 0.05). In 
group II no significant difference was found at this point (table 4). 
To evaluate the variability of home blood glucose, a two way variance 
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analysis was performed for group I and II together. No differences of be­
tween days and residual variance of blood glucoses between HI and PI 
periods were found. The diurnal variance during PI exceeded the diurnal 
variance during HI significantly (p < 0.05). 
We calculated the mean chance that the blood sugar measured during the 
out-patient clinic visit was higher during HI than during PI for each 
patient individually by comparing each blood sugar during HI with all 
blood sugars during PI. A chance of 0.5 indicates that there are no dif­
ferences in bloodsugar between HI and PI periods. In group I a signifi­
cant deviation from 0.5 was found (0.66, ρ < 0.05). 
Table 4: Mean of the median home monitored blood glucoses in mmol/l for 
the five time points of the day during HI and PI in group I and II. 
GROUP I GROUP II 
PERIOD 
8 am 
12am 
5 pm 
22pm 
3 am 
HI 
10.9+5.2 
PI 
9.4+3.2 
15.0+6.3 * 12.7±4.6 
11.0+6.1 
14.8±6.4 
13.7+5.2 
11.1+5.4 
15.0+5.7 
11.9±3.3 
(N) 
(18) 
(18) 
(18) 
(18) 
(14) 
HI 
13.5±6.0 
16.2+8.0 
14.1±9.5 
16.9±7.7 
12.8+3.7 
PI 
13.2+6.1 
13.3+4.1 
12.9+5.9 
15.3±7.4 
14.3+6.9 
(N) 
(13) 
(13) 
(13) 
(12) 
(11) 
* ρ < 0.05 tested with sign test. 
Table 5: Mean of % HbA1 (+SD) for group I and II at the start and the end 
of the different periods of the study. 
run in period period 1 period 2 
Start End End End 
group I (N=19) 12.1+2.1 * 11.1+1.4 11.4+1.8(P) 11.9±1.9(H) 
group II (N=13) 12.2+2.0 11.2+1.3 * 11.6+1.4(H) 11.5+1.3(P) 
* ρ < 0.05 
The insulin species that was used is given in parentheses. 
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НЬАІ 
During the first 6 weeks of the run-in period there was a significant 
decrease in percentage of HbAI. During HI in group II there was a small 
but significant rise in HbA1. No changes were found during PI or during 
HI in group I, nor during PI in group II (table 5). 
Hypoglycaemias. 
The mean frequency of subjective hypoglycaemias was less than once a 
week. We calculated the chance that one patient had at least one subject­
ive hypoglycaemia between two visits to the out-patients clinic during 
the HI or PI period. The mean chances were not different between HI and 
PI in group I and II (table 6). There were also no differeaces in time of 
the day of hypoglycaemias between HI and PI. 
Table 6: Chance of getting at least one subjective hypoglycaemia between 
two visits at the out-patient clinic. The differences between HI and PI 
periods are tested for each group separately. 
PERIOD 1 PERIOD 2 
Group I 0.58+0.50 (PI) П.6 +0.4 (HI) 
Group II 0.77+0.44 (HI) 0.38±0.51 (PI) 
The insulin species that was used is given in parentheses. 
The differences between periods are not statistically significant. 
Body weight. 
During the run-in period the percentual deviation of the ideal weight 
(DIW) increased by 1.6±2.9S (p < 0.05) for both groups together. No sig­
nificant DIW changes were found during PI (group I: +0.1 ± 3.55ó and group 
II: +1.1 ± 2.OS) nor during HI (group I: -1.1 + 3.0 and group II: -0.6 ± 
2.4%). 
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Insulin antibodies. 
19 Of the 32 patients were IBA positive (12 in group I and 7 in group 
ID. 
During PI no significant changes in affinity nor capacity of the two 
binding sites could be demonstrated in both groups (table 7). 
During HI no changes in affinity of both binding sites occurred in both 
groups but group II showed significant decreases of binding capacity of 
both binding sites (table 7). The decreases in binding capacities of 
group I during HI insulin were not statistically significant (table 7). 
Since both HI periods were preceeded by treatment with PI (PI period in 
group I and run-in (=PI) period in group II), we analysed the change in 
binding parameters during HI for group I and II together. Only the bind-
ing capacity of the low affinity binding site decreased for both groups 
together (table 7). Figure 2 shows the change of binding capacity of the 
low affinity binding site during HI for each individual patient. 
Discussion. 
In several studies the efficacy of hunan and porcine insulin has been 
compared. A faster absorption of human insulin was found in healthy 
volunteers (8,9,10). But apparently this difference caused no change in 
glucose levels in most short and long term clinical studies in diabetic 
patients (3,4,6,16,23,24). However in these studies the insulin dose was 
variable, so that dose adjustments could annihilate small differences 
between human and porcine insulin. 
We studied a group of patients, who injected insulin once a day. They 
were insulin dependent from the diagnosis on or had become insulin depen-
dent after a period of treatment with oral hypoglycaemic drugs. Their 
glucose regulation as a group was not sufficient. To compare the efficacy 
of HI and PI we have chosen a study design in which the insulin dose was 
only adjusted in case of unexplained severe hypo- of hyperglycemias. 
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Table 7: Mean ± S.D. parameters of insulin antibodies in IBA positive 
patients at the start and the end of HI and PI periods in group I and II. 
Group I 
Kl 
Capi 
K2 
cap2 
u n i t s 
nmol/1 
u/1 
nmol/1 
U/1 
Ρ PERIOD (N= 
s t a r t 
0.021±0.036 
1.26+3.30 
6.57±8.53 
21.19+25.83 
:12) 
end 
0.028±0.059 
1.21+3.26 
5.76+7.14 
11.48+11.80 
Η PERIOD (N=11) 
s t a r t 
0.030±0.061 
1.32+3.38 
6.14+7.35 
12.26±12.03 
I 
end 
0.015+0.010 
0.48 ±0.67 
2.91+1.84 
9.69+8.83 
Group II Η PERIOD (N=7) Ρ PERIOD (N=7) 
units start end start end 
Kl nmol/1 0.011±0.006 0.009+0.004 0.009+0.004 0.007+0.005 
Capi U/1 0.21±0.07 * 0.13+0.06 0.13+0.06 0.10+0.05 
K2 nmol/1 3.89+2.35 3.4B±2.73 3.48±2.73 2.89+3.58 
Cap2 U/1 5.37±3.27 * 3.10+2.33 3.10+2.33 4.81+6.51 
Η PERIOD of group I and II together (N=18) 
Units Start End 
Kl 
Capi 
K2 
Cap2 
nmol/1 
U/1 
nmol/1 
U/1 
0.023+0.049 
0.88+2.70 
5.26+6.03 
9.58+10.19 
0.013±0.008 
0.34+0.55 
3.13±2.25 
* 7.13±7.75 
* ρ < 0.05 
K1 and K2 are dissosiation constants and Cap 1 and Cap 2 binding 
capacities of first and second binding site of the insulin antibodies. 
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Figure 2: Changes of low affinity capapacity of insulin antibodies during 
human insulin. Group I and group II parameters are both included. 
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It is not easy to obtain a clear impression of the diabetes regulation in 
an out-patient clinic, because there is no single parameter that indicat­
es mean blood glucose and variability of blood glucose. For the assess­
ment of the mean metabolic control HbA1 levels were compared. The varia­
bility of the blood glucose was studied by means of glucosuria and home 
monitored blood glucoses. Glucosuria appears after the blood glucose has 
exceeded the renal threshold. This threshold however varies considerably 
between but also within patients (25). The blood glucose levels that are 
collected with strips at home have proved to be very reliable in recent 
studies (18), but represent only 5 points of time during 24 hours, thus 
giving an incomplete picture of the blood glucose regulation. 
A small but significant increase of the mean HbA1 level was found only 
during human insulin in group II. In both groups glucosuria during HI ex­
ceeded the one during PI from 12 a.m. to 5 p.m. In group I a slightly 
higher home blood glucose was found at 12 a.m. during HI. Using a two way 
variance analysis of home blood glucoses the diurnal variation during PI 
exceeded the one during HI. Recapitulating these partially conflicting 
results, there might be a small difference in efficacy between HI and PI, 
but we believe it is clinically not important. The faster absorbtion of 
HI, found in short term studies (8,9,10), should have resulted in lower 
blood glucoses at 12 a.m. and higher blood glucoses at В a.m. during HI. 
We found however no difference in blood glucose at В a.m. and a higher 
blood glucose at 12 a.m. and a higher glucosuria from 12 a.m. to 6 p.m. 
A second aspect of the study was to evaluate insulin antibody levels 
after changing from animal to HI. A major issue when comparing IBA levels 
is the assay method. It is not possible to compare the results between 
studies that use a different IBA assay. Using a method that describes the 
antibodies by the binding capacity of patient serum with a fixed insulin 
concentration, most of the studies found no difference (16,17), but some 
observed a decrease of insulin binding during HI (13). The second group 
of IBA assays describes insulin antibodies by two binding sites, each one 
having its own binding capacity. The only study using this kind of assay 
so far could not find a difference in antibodies after changing form PI 
to HI (13). 
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The IBA assay we used, describes the antibodies by two affinities and two 
capacities and takes into account a non specific binding for each plasma 
individually. We showed a decrease in IBA capacity of the low affinity 
binding site for the two groups together after 3 months of treatment with 
HI. In one group there was a significant decrease of the binding capacity 
of both binding sites. This decrease of IBA might have been more obvious 
if the period of treatment had been longer. Since we used an assay that 
assesses a non specific binding for each plasma individually and the 
study of Fineberg (13) used a constant non specific binding, this might 
be the reason why we did find differences and Fineberg did not. Obviously 
this decrease of IBA did not influence the clinical situation of the 
patients, using the same dose of insulin. 
We conclude that HI is effective in the treatment of diabetic patients 
and that there are no clinically important differences between HI and 
PI. Insulin antibody levels in patients previously treated with animal 
insulins tend to decrease during treatment with HI within 3 months. 
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CHAPTER 5 
COMPARISON OF THE EFFICACY OF HUMAN AND PORCINE INSULIN 
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Abstract. 
The efficacy of semisynthetic human (HI) and monocomponent porcine 
insulin (PI) in the treatment of diabetic ketoacidosis was compared in 10 
(PI) versus 11 (HI) patients in a double blind randomized study. Insulin 
(i.v. 8u/hour), fluid replacement (NaCl 0.65% and glucose 5%) and KCl 
supplements were administered according to a fixed protocol. Glucose, 
potassium, sodium, creatinine, calcium, phosphate and free insulin con­
centrations were not significantly different at the start nor at any 
later time point. At the start mean ± S.D. of pH was 7.10 ± 0.14 in the 
HI group and 7.10 ± 0.12 in the PI group. The time to reach arbitrary 
values for pH, bicarbonate, base excess and B-0H-butyrate was shorter 
during human insulin, but the differences were not statistically signifi­
cant. During human insulin the arbitrary value of 1.0 mmol/1 of aceto-
acetate was reached faster than during PI (5.2 ± 2. 6 respectively 8.4 ± 
0.9 hours, ρ < 0.05). The concentration of acetoacetate was significantly 
different between the two groups after 6 and 7 hours of insulin treatment 
(6 hours: HI 0.82 ± 0.50 mmol/1 and PI 2.19 ± 1.65 mmol/1, ρ < 0.05; 7 
hours: HI 0.51 ± 0.40 mmol/1 and PI 1.74 ± 1.54 mmol/1, p=0.05). We con­
clude that the recovery from diabetic ketoacidosis during the treatment 
with HI might be slightly faster than during treatment with PI. If this 
difference is real it does not seem of much clinical importance. 
Introduction. 
The last few years highly purified human insulin (HI) is available for 
the treatment of insulin dependent diabetic patients. Small differences 
were found in studies comparing efficacy of intravenously administered 
human and porcine insulin (PI). In volunteers the insulin induced glucose 
consunption was significantly higher during HI than during PI (1, 2) and 
HI induced a smaller decrease in serun potassium (3, 4). In other studies 
no differences in potency of HI and PI were found in volunteers (5, 6, 7) 
or in insulin dependent diabetic patients (7, 8). Theoretically it is 
possible that these differences become more obvious in the treatment of 
the most severe acute form of diabetes, the diabetic ketoacidosis (DKA). 
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So far one study compared the efficacy of HI and PI in the treatment of 
diabetic ketoacidosis (9). The study was not randomized, nor double 
blind. The control group was treated in the months before and there was 
no fixed treatment protocol as far as insulin dose, fluid replacement and 
electrolyte supplements were concerned. Using this study design no dif­
ference in efficacy between the two insulins was found. Aim of our study 
was to compare the efficacy of HI and PI m the treatment of DKA. We per­
formed a double blind, randomized, prospective clinical trial, with a 
fixed treatment protocol. 
Subjects, materials and methods. 
Design of the study. 
Diagnosis of DKA was made on clinical grounds and confirmed by hypergly-
caemia, ketonuna (Gluketur teststnps Boehnnger) and an arterial pH 
below 7.25. After the diagnosis was confirmed patients were randomized 
for the double blind administration of HI or PI. Treatment was instituted 
according to a fixed protocol, of which the efficacy in severe keto­
acidosis has been demonstrated earlier for PI (10). 
1. NaCl 0.65% was used as infusion fluid. During the first 6.5 hours 5000 
ml were infused, of which 1000 ml were administered in the first 30 
minutes. After the arterial pH had reached 7.35, 1000 ml was admin­
istered every 4 hours. When the bloodsugar had reached a level of 12.0 
mmol/1 NaCl 0.65% was substituted by glucose 5Й. Bicarbonate therapy 
was not used, unless the arterial pH was below 7.0 at admission and 
had not increased after 2 hours of treatment. This was the case in one 
patient who recieved HI. 
2. 8 U of insulin per hour were infused i.V. continuously by pump after 
the result of the plasma potassium concentration had become availa­
ble. The insulin used was monocomponent human or porcine Actrapid. The 
syringe containing insulin was filled with 1 ml(=40 U) Actrapid in­
sulin, 10 ml pasteurised human plasma protein solution and 29 ml NaCl 
0.9%. 
87 
3. If at any point of time the plasma potassium level was below 5.0 
mmol/1, 15 mmol KCL were added to every 500 ml of infusion fluid. 
During treatment venous blood samples were collected from a separate 
catheter every hour from time point zero, being the starting-point of 
insulin therapy, for the measurement of glucose, sodium, potassium, IRI 
(total + free), B-OH-butyrate (BOHB) and acetoacetate (ACAC). Arterial 
blood gas analysis was also performed every hour. At the start and every 
4 hours after the start of treatment creatinine, calcium and phosphate 
were determined in venous blood samples. 
This protocol was followed until the pH had reached a level of 7.35. 
The study was approved by the ethical committee of our hospital and pa-
tients or relatives gave informed consent. 
Patients. 
Ten patients were treated with porcine insulin (PI) and eleven with human 
insulin (HI). Between these two groups there were no significant differ-
ences in sex, state of conciousness, age, duration of insulin therapy 
before DKA, basal levels in venous blood of glucose, BOBH, ACAC, crea-
tinine, calcium, phosphate, sodium, potassium, and IRI. Also no dif-
ferences were found in arterial pH, bicarbonate and base excess. In group 
PI, 1 out of 10 and in group HI, 3 out of 11 patients had not received 
insulin treatment before. This difference is not statistically signifi-
cant. For the data see table 1. As appears from table 1 not all para-
meters were available at the start. After one hour of treatment however, 
all parameters were available for all patients and again no significant 
differences were found. The condition that precipitated DKA was a res-
piratory tract infection in 2 patients of group PI. In the other 8 pa-
tients of this group no cause was discovered. In group HI, respiratory 
tract infection was present in 1 patient, urinary tract infection in 2, 
enteric infection in 1, 2 patients had omitted insulin therapy and 1 
patient had a severe acute pancreatitis. The cause of the ketoacidosis 
was not known in the other 4 patients. Two patients of group PI and 4 of 
group HI used other medications in addition to insulin, mostly anti-
biotics. 
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Table 1: Patients, biographical and biochemical data at the start of 
treatment. Data are given as mean + S.D. 
Insulin origin 
N 
Consciousness abnorm 
Age 
Age range 
Duration of diabetes 
Treated with insulin 
Duration of insulin 
al 
mellitus 
ι before 
therapy 
Other drugs than insulin 
Glucose 
Arterial pH 
BOHbutyrate (N) 
Acetoacetate (N) 
Bicarbonate 
Base excess 
Creatinine 
Calcium (N) 
Fosfate (Ν) 
Sodiun 
Potassium 
Free insulin (N) 
Units 
years 
years 
years 
number 
years 
number 
mmol/1 
mmol/1 
mmol/1 
mmol/1 
mmol/1 
μιηοΐ/ΐ 
mmol/1 
mmol/1 
mmol/1 
mmol/1 
mU/1 
Porcine 
10 
5 
54.5±19.7 
15.3-79.5 
16.7±12.7 
9 
13.6+14.0 
2 
32.9+17.θ 
7.10±0.12 
8.9412.67 
3.16±0.88 
6.3+5.0 
-21.8+6.6 
254±134 
2.40+0.05 
1.50±0.24 
138±7 
5.0+0.9 
11 ±9 
* 
(6) 
(6) 
(4) 
(4) 
(4) 
Human 
11 
3 
47.0+22.9 
14.3-77.7 
19.7+13.2 
8 
19.6±11.2 
4 
34.5+15.4 
7.10±0.14 
7.89+2.35 
2.97±1.46 
6.5+4.0 
-22.0+6.7 
224±85 
2.40+0.27 
1.60±0.36 
138+6 
5.0±1.1 
10±6 
(10) 
(10) 
(8) 
(8) 
(8) 
ρ < 0.05 
Analytical methods. 
Plasma glucose was analysed using the Hofman method (11). Arterial pH, 
bicarbonate and base excess were measured by a Corning 175 automatic 
blood gas analysis system. Venous blood was collected in ice-cooled tubes 
and extracted within 30 minutes by perchloric acid for the determination 
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of BOHB and ACAC by an enzymatic method (12). The Nakagawa (13) method 
was used for the determination of total and free IRI in venous serum. 
Routine laboratory methods were used for the other parameters. 
Statistics. 
Results are expressed as mean ± SD. For the analysis of 2 by 2 con­
tingency tables the Fisher exact test was used. For other statistical 
analyses the Wilcoxon 2-sample test for unpaired observations was used. 
Regression was analysed by Pearsons method. After 7 hours of treatment so 
many patients had recovered from DKA that further statistical analysis of 
differences between PI and HI in the remaining patients was not possible 
anymore. 
Glucose(mmo!/I) 
6 0 -
40 
20-
i 1 1 1 1 г 
0 2 U 6 
Hours of insulin trealment 
Figure 1 : Mean (·) and individual (o) glucose levels during the first 7 
hours from the start of PI and HI treatment untili the fluid infusion was 
changed from saline 0.65SÍ to glucose 55S or the pH reached a level of 
7.35. At no time point significant differences of mean glucose were found 
between PI and HI treated patients. 
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Results. 
1. Complications. 
During the treatment one patient became hypoglycaemic, because the 0.65% 
saline infusion was substituted too late by 5% glucose. This patient was 
treated with PI. 
One patient, a 79 years old woman, died during the treatment. She was 
admitted to the hospital in an unconscious state with an arterial pH of 
7.18 and a glucose level of 60.3 mmol/1. After the start of the protocol 
the pH recovered to 7.27 and the glucose had decreased to 35 mmol/1 after 
6 hours. She had become somnolent and complained about pain in the ab­
domen. After 7 hours the pH deteriorated again despite a decrease of BOBH 
and ACAC levels. 10 Hours after admission the patient died in shock. At 
autopsy a thrombosis of the arteria mesenterica superior and a massive 
infarction of the small gut was found. This patient was treated with HI. 
Her data have been included in the results. All other patients recovered 
from the DKA within 24 hours. 
Table 2: Hours needed to reach the indicated arbitrary value of the para­
meters of diabetic ketoacidosis during the treatment with porcine and 
human insulin. Data are expressed аз mean ± SD. 
Glucose 
pH 
Bicarbonate 
Base excess 
BOHbutyrate 
Acetoacetate 
Value 
12 mmol/1 
7.30 
15 mmol/1 
-10 mmol/1 
1 mmol/1 
1 mmol/1 
Po reine insulin 
4.7±3.5 
8.3±2.0 
8.1+2.6 
10.5+8.8 
9.2±1.0 
8.4+0.9 
Ρ 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
0.04 
Human insulin 
5.5±4.0 
7.5+2.0 
6.1+1.6 
7.8+5.7 
8.4±1.1 
5.2+2.6 
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2. Plasma glucose concentration. 
No difference in glucose level was found between the two groups at the 
start (table 1). During the first 7 hours the glucose concentrations 
decreased in both groups by the same rate, so that no significant differ­
ences could be found at any point of time (figure 1). As can be seen in 
figure 1 the individual glucose concentrations varied considerably. This 
interpatient variation did not differ significantly between the groups 
(variance analysis). The time necessary to reach a glucose level of 12.0 
mmol/l was not different for the two groups (table 2). 
7 00 
6 80 
г 
0 2 U 6 
hours of insulin treatment 
Figure 2; Mean (·) and individual (o) pH values during the first 7 hours 
from the start of PI and HI treatment untili the protocol was stopped. At 
no time point significant differences of mean pH were found between PI 
and HI treated patients. In the HI treated group 1 patient died in shock 
("f) and one patient received bicarbonate once (Bic). 
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3. Ketoacidosis. 
At the start of the insulin therapy no significant differences in the 
parameters of ketoacidosis were found between the two groups (table 1). 
Figure 2 shows the effect of the therapy on the pH for the two groups. 
Only one patient (HI group) received once 10G ml МаНСОз 4.2?ί. No differ­
ences were found at any point of time between the two groups. The time 
needed to reach a pH of 7.30 was not significantly different for the two 
groups (table 2). 
Acetoacetate (mmol/l 
Porcine insulin 
60 
4 Ο­
ΣΟ­
Ι 1 г 
0 2 4 6 
Hours of insulin treatment 
Figure 3; Mean (·) and individual (o) acetoacetate levels during the 
first 7 hours from the start of PI and HI treatment as long as this 
ketoacid was measured. After 6 (p < 0.05) and after 7 hours (p=0.05) mean 
acetoacetate levels of patients treated with HI were lower than the mean 
values of the patients treated with PI. 
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As was the case for pH, the time needed for bicarbonate, base excess, 
BOBH and ACAC to reach a certain arbitrary level, was in the HI group a 
little shorter than in the PI group, but this difference reached sta­
tistical significance only for ACAC (table 2). When we analysed the ACAC 
levels each hour the difference between group PI and HI became signifi­
cant after 6 hours (2.19 ± 1.65 versus 0.B2 ± 0.50, ρ < 0.05) and 7 hours 
(1.74 ± 1.54 versus 0.51 + 0.40, p=0.05) (Fig. 3). 
4. Potassium and sodium concentrations. 
No significant differences of potassium and sodium levels were found at 
the onset of treatment (table 1). The sodium levels did not differ signi­
ficantly between HI and PI treatment at any of the first 7 hours of 
treatment. After 3 hours of treatment the potassium level was 4.2 ± 0.6 
mmol/1 during HI (N=10) and 5.0 + 0.7 mmol/1 during PI (N=10) (p=0.023). 
No significant differences in potassium concentration were found at other 
times. 
5. Calcium, phosphate and creatinine concentrations. 
No significant differences between group HI and PI were found for these 
parameters at the start (table 1). Neither were significant differences 
found after 4, 8 and 24-4B hours of treatment (figure 4). After 24-4B 
hours the creatinine concentration was normalized almost completely. 
Phosphate concentration were still very low after 24-48 hours. 
6. IRI. 
Free IRI was measured at the start in 4 out of 10 patients in group PI 
and 8 out of 11 patients in group HI. These free IRI levels were not sig­
nificantly different (table 1). In all patients free IRI levels were 
measured from 1 hour after the start of insulin therapy on. As shown in 
figure 5 no differences in free insulin were found at any of the first 7 
hours between HI and PI. There was a considerable individual variation of 
free IRI concentrations, although all patients received 8 U of insulin 
per hour. For every patient a mean bound and free insulin concentration 
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Creatinine 
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Figure 4; Mean ± SD creatinine, calcium and phosphate levels at the start 
and after 4, θ and 24-48 hours of treatment with PI or HI. At no time 
point significant differences between PI and HI treated patients were 
found. 
during the first 7 hours was calculated. Nor for the HI group (R=-0.26, 
NS) nor for the PI group (R=-0.02, NS) nor for both groups together 
(R=-0.13, NS) there was a significant correlation between mean free and 
mean bound insulin. 
No significant correlation was found between mean free IRI concentration 
and increase of pH per hour for group HI (R=0.02, NS), for group PI 
(R=-0.29, NS) and for HI and PI groups together (R=-0.03, NS). The 
patients with the lowest mean free IRI had levels of 39 (PI) and 42 (HI) 
mU/1. Their recovery was not delayed. 
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Figure 5: Mean ( · ) and ind iv idua l (o) free i nsu l i n leve ls during the 
f i r s t 7 hours of treatment wi th PI and H I . Figures are given u n t i l i the 
protocol was ended. At no time point s i gn i f i can t d i f ferences between PI 
and HI t reated pat ients were found. 
Discussion. 
This study compared the e f f i cacy of monocomponent HI and PI in the t r e a t -
ment of d iabet ic ketoacidosis . The rate of normal izat ion of glucose, pH, 
bicarbonate, base excess and BQBH was the same during HI and P I . No d i f -
ferences were found in the leve ls o f ca l c i un , phosphate and c rea t in ine 
a f ter 0, 4 , θ and 24-48 hours. Serum phosphate was s t i l l very low a f t e r 
24-48 hours as reported before ( 1 4 ) . The mean concentrat ion o f ACAC de­
creased faster during H I . When we looked closer at the data a l l parame­
t e r s of ketoacidosis tended to improve faster during H I , but the only 
s i g n i f i c a n t d i f ference was the rate of decrease of ACAC. Therefore there 
could be an o v e r a l l faster improvement of DKA during H I . A s l i g h t d i f f e r -
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enee in the rate of recovery between the two groups could be connected 
with a dissimilarity before the start of treatment. We feel that we may 
conclude from the data of table 1 that the condition of the patients in 
the PI group was not worse than in the HI group. There were no signifi-
cant differences in the parameters of metabolic derangement. Admittedly, 
BOBH and ACAC were a little higher in the PI group, but pH and base ex-
cess were the same and glucose was slightly higher in the HI group. Also 
there was no difference in age between the groups. 
Only one study compared the efficacy of human and porcine insulin during 
the treatment of DKA so far (9). No differences were found between the 
effects of HI and PI insulin. However this study was not randomized, nor 
double blind. The insulin infusion rate was not kept constant and no fix-
ed protocol was used for fluid and electrolyte supplements. Moreover, 
BOBH and ACAC were not measured. 
Clark et al. (15) infused Intralipid and compared the antiketogenic ef-
fects of HI and PI in 9 healthy subjects. They found significantly lower 
levels of BOBH during infusion of HI and no difference in ACAC level. 
These findings point in the same direction as our results. 
In several studies high dose and low dose infusion of insulin proved to 
be equally effective in the treatment of DKA (10, 16). Hypoglycaemias 
however occurred more frequently during high dose insulin infusion. In 
our study 8 U of insulin per hour were infused. At admission insulin 
levels were low. During treatment there was a considerable variation of 
free insulin concentrations between patients that could not be explained 
by insulin binding by antibodies, because we did not find a negative cor-
relation between free and bound insulin. The lowest mean steady state 
free insulin concentration was 39 mU/1, indicating that an insulin in-
fusion still lower than 8 U per hour, may result in insulin levels that 
are suboptimal for the treatment of DKA, for it has been shown that glu-
cose uptake in muscle takes place between insulin levels of 20 and 200 
mU/1 (17). In our study no systematic difference was found between the 
steady state levels of free insulin in the PI and HI groups which is in 
agreement with published data about the pharmacokinetics of both kinds of 
insulin (2, 5, 6, 7, 18). 
We conclude that human insulin is effective in the treatment of DKA. The 
recovery from DKA during treatment with HI might be slightly faster than 
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during treatment with PI. If this difference is real, it seems of not 
much clinical relevance. 
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Summary. 
The summary intends to give information to those who are interested in 
only one or a few chapters and to those who have not the time to read the 
thesis in detail. 
In chapter 1 the production process of semisynthetic and biosynthetic 
human insulin is described. Subsequently clinical research that has been 
performed so far on human insulin is reviewed. Comparing porcine and 
human insulin most studies found no difference in efficacy, but in some a 
faster action of insulin after subcutaneous injection has been describ-
ed. Although the hypoglycaemic effect of human insulin was the same as 
that of porcine insulin, one study found a less pronounced reaction of 
counterregulatory hormones after human insulin. This was not confirmed by 
several other studies. Whether or not human insulin is more effective 
than porcine insulin in the treatment of diabetic ketoacidosis is not 
clear, so far. When human insulin is used for at least 6 months it seems 
less immunogenic than porcine insulin in newly diagnosed diabetic pa-
tients. If human insulin is also less immunogenic in patients previously 
treated with highly purified porcine insulin has not been clearly shown 
yet. 
The different assays for insulin antibodies are described in the follow-
ing paragraph. Since these methods are fundamentally different, it is not 
possible to compare clinical studies on insulin antibodies. Besides these 
assay problems, the clinical relevance of insulin antibodies has not been 
completely established. The presence of IBA may be related to rare cases 
of allergy and may be accompanied by a higher incidence of hypoglycaemias 
and a worse control of blood sugar regulation than in the absence of 
antibodies. It has also been suggested that insulin antibodies are relat-
ed to microvascular disease. Patients that do not develop insulin anti-
bodies have longer remissions after the start of insulin treatment. 
The insulin antibody assay that was used in our studies is described in 
chapter 2. The binding process of insulin by insulin antibodies is de-
scribed by two different groups of binding sites, each having its own 
affinity and ciLdCi.y. The non specific binding of insulin in the assay 
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was estimated as a distinct parameter for each individual plasma. From 19 
insulin antibody positive patients plasma was collected every 3 months, 
during a period of 9 months. The assay was performed in 4 runs. Plasmas 
of each individual patient were always analysed in the same run of the 
assay. In all four runs intra-patient variance of non specific binding 
proved to be smaller than between-patient variance. This indicates that 
this non specific binding is patient dependent and therefore should be 
estimated for each patient individually. 
The efficacy, the immunogenicity and the effect on residual B-cell func-
tion of human and porcine insulin in newly diagnosed type I diabetic 
patients is described in chapter 3. In this randomized, double blind, 
prospective study no clear differences between human and porcine insulin 
were found. The only difference with a possible clinical importance was 
that during treatment with human insulin the between days variance of 
home blood glucose was smaller than during porcine insulin. 
In 5 patients treated with human insulin and in 7 patients treated with 
porcine insulin, insulin binding antibodies were analysed from 0 to 18 
months, with an interval of 6 months. No differences between the two 
groups were found. However, our conclusions on this point must be guard-
ed, because of the rather small number of patients, that completed this 
study so far. 
In chapter 4 a double blind, randomized, prospective, cross-over study is 
described in which the efficacy and immunogenicity of human and porcine 
insulin have been compared in patients that were previously treated with 
animal insulins. 32 Patients completed the study. All the patients used 
long-acting insulin once a day, Monotard insulin with or without Actrapid 
insulin. After a run-in period of 3 months, in which the patients used 
porcine insulin only, they were treated with human or porcine insulin for 
three months. After this time the insulin species was switched for 
another three months. In the group that received human insulin first a 
slight but significant increase of HbA1 was observed during human 
insulin. In the group that received porcine insulin first the mean blood 
glucose during human insulin at 12 a.m. exceeded the one during porcine 
insulin. In both groups the glucosuria from 12 a.m. to 6 p.m. was higher 
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during human insulin. Although the blood glucose concentration was only 
different at 12 a.m. in one group, the diurnal variance of these glucose 
concentrations during porcine insulin exceeded the diurnal variance 
during human insulin in both groups together. The binding capacity of the 
low affinity antibodies decreased during human insulin and did not change 
significantly during porcine insulin. 
So, small differences in metabolic control could be demonstrated between 
human and porcine insulin. Insulin antibody concentration decreased 
during 3 months of treatment with human insulin, indicating a lower 
immunogenicity compared to porcine insulin. 
A study comparing the efficacy of semisynthetic human and monocomponent 
porcine insulin in the treatment of diabetic ketoacidosis is described in 
chapter 5. Patients presenting with an arterial pH equal or below 7.25 
were randomly assigned to a double blind treatment with human (N=11) or 
porcine (N=9) insulin. The fixed treatment protocol consisted of 8 U/hour 
of insulin intravenously by a continuously running pump, fluid replace­
ment by NaCl 0.65л and glucose 5% and potassium supplements when the 
plasma potassium level was found to be below 5.0 mmol/1. A number of 
parameters was measured every hour. No significant differences were found 
at any time point for glucose, pH, bicarbonate, base excess and B-OH-
butyrate. The time of recovery to arbitrary levels of pH, bicarbonate, 
base excess and B-OH-butyrate was not significantly shorter during human 
insulin. The only significant difference found, was the shorter recovery 
time for acetoacetate. After 6 and 7 hours of treatment the plasma con­
centrations of acetoacetate were significantly lower during human 
insulin. From these data we conclude that in the experimental circum­
stances described above, human insulin is slightly more effective in the 
treatment of ketosis in diabetic ketoacidosis. 
Summarizing all the results of the clinical studies, in which a lot of 
parameters for diabetic control were analysed, human insulin differs only 
slightly from porcine insulin as far as efficacy is concerned. These 
small differences were only seen in diabetic patients who used the same 
dose of human -"id porcine insulin. When the aim was to achieve normo-
glycaemia witi . гее insulin dose regimen, human and porcine insulin 
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proved to be equally effective. Both in newly diagnosed patients and in 
patients who were previously treated with animal insulin, the variance of 
home blood glucose concentrations during porcine insulin exceeded the 
variance during human insulin. In patients who were treated with monocom­
ponent porcine insulin before, human insulin treatment resulted in a de­
crease of insulin binding antibodies within 3 months. In a smaller number 
of newly diagnosed patients no differences in insulin antibody parameters 
were found between human and porcine insulin treatment after a period up 
to 1Θ months. Human insulin proved to be slightly more effective in the 
treatment of ketosis in patients who presented with ketoacidosis. Except 
for the variance of home blood glucose concentrations, that was not 
assessed in other studies, our results on efficacy of human insulin are 
in concordance with recently published studies. However, the decrease of 
insulin binding antibodies within 3 months in patients previously treated 
with porcine insulin was not found by other investigators. This differ­
ence could perhaps be explained by the fact that we used a more thorough 
assay for insulin binding antibodies. 
Overlooking studies from other authors and our studies, we may conclude 
that the probable replacement of animal insulins by human insulin within 
the next 10 years, will cause no problems for physicians and patients, 
but the question whether this replacement will be a benefit from the 
clinical point of view still remains open. 
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Samenvatting. 
Gepoogd is in de Nederlandse samenvatting medische en wetenschappelijke 
"geheimtaal" zoveel mogelijk te vermijden zodat deze ook voor niet inge-
wijden enigszins leesbaar is. 
In hoofdstuk 1 wordt in het kort beschreven wat er tot nu toe bekend is 
over het gebruik van menselijke insuline bij de behandeling van suiker-
ziekte. In het verleden werd steeds van dieren afkomstige insuline (rund, 
varken) gebruikt. Dierlijke insuline is in geringe mate anders van che-
mische samenstelling dan menselijke insuline. Sinds kort zijn er 2 ma-
nieren in gebruik om menselijke insuline te maken: door chemische veran-
dering van varkensinsuline en door manipulatie van materiaal waarin de 
erfelijke eigenschappen liggen verankerd (DNA). Deze twee productie-
methoden worden in hoofdstuk 1 besproken. Bij de mens wordt insuline 
onder de huid gespoten om van daar uit in het bloed terecht te komen waar 
de voornaamste functie het verlagen van het suikergehalte is. Sommige 
onderzoekers vonden dat de menseljke insuline sneller in het bloed komt 
dan varkensinsuline en dat het bloedsuikergehalte ook sneller daalt. Een 
groter aantal andere onderzoekers vond geen verschil. Wanneer er te veel 
insuline en daardoor te weinig suiker in het bloed is, krijgt een dia-
betespatiënt een zeer onaangename sensatie, een zogenaamde hypoglyc-
aemie ("hypo"). Deze sensatie wordt mede veroorzaakt door bepaalde stof-
fen (hormonen) die als reactie op het lage bloedsuikergehalte vrijkomen. 
In één studie was de uitstorting van deze bloedsuikerverhogende stoffen 
na een te laag bloedsuikergehalte minder groot na menselijke dan na var-
kensinsuline. Verscheidene studies, die dit verschil ook zochten, hebben 
het niet kunnen aantonen. Wanneer een diabetespatiënt, die afhankelijk is 
van insuline, te lang te weinig insuline krijgt toegediend treedt er een 
situatie op waarbij het bloedsuikergehalte zeer hoog kan worden en het 
bloed zuur wordt. Deze toestand, diabetische ketoacidose genaamd, leidt, 
indien er niet wordt ingegrepen, tot de dood. Indien de werkaamheid van 
menselijke en varkensinsuline verschillend is, zou dit bij de behandeling 
van deze ernstigste vorm van diabetes duidelijk kunnen worden. In één 
studie werd dit punt onderzocht, maar er werd geen verschil gevonden. Op 
de organisatie van die studie is echter nogal wat kritiek uit te oefenen 
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zodat de vraag, welke van de twee insulinesoorten effectiever is bij de 
behandeling van ernstige diabetische ontregelingen, nog niet beantwoord 
is. 
Wanneer men bij de mens lichaamsvreemde stoffen inspuit zal hij hierop 
reageren met het maken van antistoffen, die zich aan deze vreemde stoffen 
binden, waarna ze opgeruimd kunnen worden. Het is bekend dat deze anti-
stoffen ook tegen dierlijke insuline gemaakt worden en dat een merendeel 
van de diabetespatiënten ze bezit. Aangezien varkensinsuline meer lijkt 
op menselijk insuline dan runderinsuline worden hiertegen ook minder 
antistoffen gemaakt. Daar menselijke insuline, dat gemaakt wordt op de 
twee bovenstaande manieren, gelijk is aan de stof die in de alvleesklier 
van de mens wordt gemaakt, zou het lichaam deze insuline niet als vreemd 
moeten beschouwen. In verschillende onderzoeken is echter al aangetoond 
dat ook tegen menselijke insuline antilichamen worden gemaakt. Wel bleek 
in sommige studies dat er minder antilichamen tegen menselijke dan tegen 
varkensinsuline worden gemaakt. Andere studies konden dit niet bevesti-
gen. Bij patiënten met grote hoeveelheden antistoffen tegen insuline kan 
een insulineongevoeligheid ontstaan, dat wil zeggen dat ze zeer grote 
hoeveelheden insuline moeten gebruiken om het bloedsuikergehalte omlaag 
te krijgen. De betekenis van geringere hoeveelheden antistoffen voor de 
patient is niet duidelijk. Mogelijk hebben patiënten met insuline anti-
stoffen meer kans op hypoglycaemien, is hun bloedsuikergehalte minder 
goed in te stellen en hebben ze meer kans op bloedvatafwijkingen op de 
lange duur. 
In hoofdstuk 2 is de methode van insuline antilichaambepaling beschre-
ven. De manier waarop insuline door de antilichamen wordt gebonden is 
nogal ingewikkeld. Het bindingsproces kan beschreven worden door een 
getal, dat de gretigheid van de antilichamen tot binding (affiniteit) 
aangeeft, en een getal, dat aangeeft hoeveel er in totaal kan worden ge-
bonden (capaciteit). Insuline-antistoffen blijken uit twee groepen te 
bestaan: de eerste heeft een grote affiniteit, maar een lage capaciteit 
en de tweede heeft een kleine affiniteit, maar een grote capaciteit. 
Naast deze binding aan antistoffen wordt insuline ook nog aan andere 
stoffen gebonden (niet-specifieke binding). Over het algemeen wordt aan-
genomen dat deze niet-specifieke binding kunstmatig is en wordt veroor-
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zaakt door de methode die in het laboratorium gebruikt wordt om antistof-
fen te bepalen. Om nu specifieke binding te berekenen, wordt van de 
totale binding de niet-specifieke binding, die voor alle bepalingen het-
zelfde is, afgetrokken. Bij onze manier van antistofbepaling werd voor 
ieder apart bloedmonster naast de affiniteit en capaciteit van de twee 
soorten antilichamen ook de niet-specifieke binding bepaald. Na bewerking 
van de uitkomsten bleek dat de hoeveelheid niet-specifieke binding niet 
alleen afhangt van de laboratoriummethode, maar ook van de patient. Dit 
betekent dat deze laatste voor iedere patient bepaald moet worden en dat 
niet een vaste hoeveelheid binding van iedere totale binding mag worden 
afgetrokken om de specifieke te berekenen. 
In hoofdstuk 3 wordt een studie beschreven waarin de effectiviteit en het 
antilichaam-opwekkend effect (antigeniciteit) van varkens- en menselijke 
insuline vergeleken werden, bij patiënten die insuline afhankelijk waren 
en tevoren nog niet met insuline behandeld waren. Hiervoor werden 11 
patiënten met varkens- en 9 patiënten met menselijk insuline behandeld. 
De regulering van de bloedsuikers was in beide groepen gelijk. Het enige 
verschil dat werd gevonden was dat het bloedsuikergehalte van de ene op 
de andere dag minder varieerde tijdens menselijk insuline. Bij 5 patiën-
ten die behandeld waren met menselijk insuline en bij 7 die behandeld 
waren met varkensinsuline werden op gezette tijden insuline antilichamen 
bepaald. Na 6, 12, 15 en 1B maanden waren er geen verschillen wat betreft 
insuline-antilichamen tussen deze 2 groepen. 
In hoofdstuk 4 wordt een studie beschreven waarin de effectiviteit en de 
antigeniciteit van varkens- en menselijke insuline wordt vergeleken bij 
32 patiënten die tevoren dierlijke insuline inspoten. Hiertoe kregen de 
patiënten eerst 3 maanden varkensinsuline en vervolgens "dubbelblind", 
dat wil zeggen zonder dat de patient of de behandelend arts wisten welke 
insulinesoort het was, 3 maanden varkens- en daarna 3 maanden menselijk 
insuline (groep 1) of in omgekeerde volgorde (groep 2). De hoeveelheid 
insuline die de mensen eenmaal per dag spoten werd zo weinig mogelijk 
veranderd. In groep 1 bleek het gemiddelde bloedsuikergehalte om 12 uur 
's middags tijdens menselijk insuline hoger te zijn. In groep 2 bleek het 
gemiddelde bloedsuikergehalte, over een periode van ongeveer 6 weken 
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gemeten, in geringe mate toe te nemen tijdens menselijk insuline. In 
beide groepen was de hoeveelheid suiker in de urine van 12 tot 18 uur 
hoger tijdens menselijk insuline. 19 Patienten hadden insuline anti-
lichamen. Gedurende behandeling met menselijk insuline daalde de capaci-
teit van de groep antilichamen met lage affiniteit. 
In hoofdstuk 5 wordt een studie beschreven waarin de effectiviteit van 
varkens- en menselijk insuline wordt vergeleken bij de behandeling van 
diabetische ketoacidose. 11 Patienten werden met menselijk en 10 met 
varkensinuline behandeld. Behalve wat betreft het verschil in insuline-
soort was de behandeling gelijk voor beide groepen. De verbetering van de 
zuurgraad en van het bloedsuikergehalte was niet verschillend bij beide 
groepen. Tijdens een diabetische ketoacidose wordt de verzuring van het 
bloed grotendeels veroorzaakt door 2 zogenaamde ketozuren: acetylazijn-
zuur en B-hydroxyboterzuur. Het verdwijnen van acetylazijnzuur was duide-
lijk sneller tijdens menselijk insuline. Bij onze manier van behandelen 
bleek menselijk insuline dus iets effectiever te zijn dan varkensinsuline 
bij de behandeling van diabetische ketoacidose. 
Wanneer we de resultaten van de drie studies, waarin wij menselijke en 
varkensinsuline vergeleken bij de behandeling van diabetespatiënten 
samenvatten, blijkt dat er geen grote verschillen zijn. De werkzaamheid 
van menselijk insuline is iets anders, zonder dat dit betekenis voor de 
patiënten heeft. Bij mensen, die tevoren met dierlijke insuline werden 
behandeld, blijkt menselijke insuline binnen 3 maanden een vermindering 
van de antistoffen te veroorzaken. Mogelijk is menselijke insuline effec-
tiever dan varkensinsuline bij de behandeling van diabetische ketoaci-
dose. Gezien studies in de literatuur en de resultaten van ons onderzoek 
zal de vervanging van dierlijke door menselijke insuline gedurende de 
komende 10 jaar geen problemen opleveren. Het blijft nog de vraag of deze 
vervanging iets gunstige oplevert voor de patiënten. 
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Woorden van dank. 
Allereerst wil ik alle patiënten die aan de verschillende studies hebben 
deelgenomen danken voor hun enthousiaste medewerking. Dankzij hun inzet 
konden de vele gegevens verzameld worden. 
De "suikerzusters" van de polikliniek bepaalden ontelbare keren het glu-
cosegehalte in urinemonsters en even vaak werden bij patiënten bloed 
monsters afgenomen. Ook de verpleegkundigen van de klinische afdelingen 
B40 en B60 wil ik danken voor de steeds enthousiaste hulp die zij, even-
als de verpleegkundigen op de polikliniek, boden bij het instrueren van 
nieuwe diabetespatiënten en niet te vergeten voor de assistentie die zij, 
zowel overdag, maar vooral ook 's nachts, boden bij de vele behandelingen 
voor diabetische ketoacidose. 
Een grote hoeveelheid laboratoriumwerk is verzet door R. Hermsen. Hem en 
ook de andere medewerkers van het laboratorium voor Chemische en Experi-
mentele Endocrinologie (hoofd Prof.dr. T. Benraad) wil ik danken voor de 
vele bepalingen die verricht zijn en voor de hulp bij het beschrijven van 
de insuline antilichaamassay. De routinebepalingen werden nauwkeurig als 
altijd verricht op het laboratorium van Inwendige Geneeskunde (hoofd 
Prof.dr. A.P. Jansen) . 
De statistische analyse vond plaats met accurate medewerking van de 
Mathematisch Statistische Adviesafdeling (hoofd Dr. Ph. van Eiteren). 
Dankzij deze hulp is mijn inzicht in de statistische methodieken, hope-
lijk blijvend, verdiept. 
De heer G. van Lingen van de afdeling Pharmacologie (hoofd Prof.dr. J.M. 
van Rossutn) maakte het computermodel ter beschrijving van pharmacon-
receptor interactie geschikt voor de beschrijving van insulinebindende 
antilichamen. Naast het mogelijk maken van de bestudering van niet-spe-
cifieke binding bij de bepaling van insulinebindende antilichamen, heeft 
het gebruik van dit programma mijn interesse voor het gebruik van compu-
ters gewekt. 
Het aselect indelen van de patiënten en het dubbelblind verstrekken van 
de insulinepreparaten is zeer accuraat verricht door de medewerksters van 
de Apotheek (hoofd' Prof.dr. E. van der Kleyn). 
Meerdere malen is een beroep gedaan op Drs. E. de Graaff en later Drs. 
S. Bakker van de Medische Bibliotheek, die steeds weer nieuwe literatuur 
uit de computer toverden. 
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De collega-artsen van one afdeling waren steeds alert op de diagnose 
nieuwe type I diabetes en diabetische ketoacidose en fungeerden als voor­
uitgeschoven posten om de studies te "vullen". Hiervoor en voor het 
interesse dat zij steeds getoond hebben in mijn werk wil ik hen danken. 
De heer C.P. Nicolasen van de afdeling Medische Illustratie heeft met 
vakmanschap de figuren en schema's getekend. Deze tekeningen werden door 
de afdeling Medische Fotografie (hoofd. A. Reynen) op de gevoelige plaat 
vastgelegd. 
De steun, zowel immaterieel als financieel, die ik van NOVO Nederland heb 
gekregen, was steeds adequaat en maakte een soepel verloop van de studie 
mogelijk. Op deze plaats wil ik dan ook drs. С Houtzagers en de heren 
J. van Veen en B. Spaay danken voor de altijd prettige samenwerking. Dr. 
L.G. Heding en Dr. I. Jensen van NOVO Denemarken wil ik danken voor de 
kritische inbreng bij het bespreken van de resultaten van de verschillen­
de studies. 
Last but not least wil ik mijn vrouw len Creusen bedanken voor het met 
veel geduld verrichten van de tekstverwerking en het bijstaan in de vaak 
drukke tijden. Het drukklaar maken van dit proefschrift werd verzorgd 
door Mevr. D. Graven, bibliothecaresse van de Kliniek voor Inwendige 
Ziekten. 
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De schrijver van dit proefschrift werd op 23-09-51 te Sittard geboren. 
Hij legde het eindexamen gymnasium-B in 1969 op het Bischoppelijk College 
te Sittard met goed gevolg af, waarna hij in hetzelfde jaar aan zijn me-
dische studie begon aan de Katholieke Universiteit te Nijmegen. Het doc-
toraalexamen werd in 1975 en het artsexamen in 1977 behaald. Na te hebben 
voldaan aan zijn militaire dienstplicht, werd in 1978 begonnen aan de 
specialistenopleiding op de afdeling Interne Geneeskunde van het St. 
Radboudiekenhuis te Nijmegen (hoofd destijds Prof.dr. C.L.H. Majoor, 
huidig hoofd Prof.dr. A. van 't Laar). In juni 1981 begon hij op de afde-
ling Algemeen Interne Geneeskunde van het St. Radboudziekenhuis met de 
studies die tot dit proefschrift geleid hebben. In 1983 werd hij inge-
schreven als internist. Momenteel is hij werkzaam op de afdeling Algemeen 
Interne Geneeskunde. Hij is getrouwd met len Creusen en heeft twee doch-
ters, Anke en Irith. 
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STELLINGEN 
1. Voor de behandeling van insuline-afhankelijke diabetes is varkens-
insuline even effectief als menselijke insuline. 
2. De bindingscapaciteit van insulinebindende antilichamen met lage 
affiniteit, die ontstaan tijdens behandeling met dierlijke insuline, 
neemt af wanneer de patiënten vervolgens met menselijke insuline be-
handeld worden, maar dit geringe verschil in immunogene eigenschappen 
heeft waarschijnlijk geen klinische betekenis. 
3. Bij de behandeling van diabetische keto-acidose is een intraveneuze 
toediening van θ eenheden insuline per uur voldoende, ook als er 
insulinebindende antilichamen zijn. 
4. De niet specifieke binding van insuline in een "equilibrium binding 
assay" voor insulinebindende antilichamen is met alleen afhankelijk 
van de bepalingscondities maar ook van individuele plasmafactoren. 
5. Ook bij diabetespatiënten die intensief begeleid worden, resulteert 
het eenmaal daags injiceren van langwerkende insuline meestal niet in 
een acceptabele metabole contrôle. 
6. De toename van de incidentie van cardiovasculaire accidenten door 
roken bij patiënten met een lichte hypertensie is groter dan de af-
name van de incidentie door medicamenteuze therapie. 
MÍC working party: MFC t r i a l of treatment of mild hyper-
tension: principal results, frit. I*fed. J . 1985; 291: 97-104. 
7 . B i j s l ech t i n g e s t e l d e d iabe tespa t i ën ten draagt met -enzymat i sche 
g l u c o s y l e n n g van LDL-apoB, met a l s gevolg een ver t raagde k l a r i n g en 
verhoogde sp iege ls van LDL i n het b loed , moge l i j k b i j t o t de vroeg-
t i j d i g e o n t w i k k e l i n g van a thé rosc lé rose . 
Steirbrecher, W.P. and Witztun, J.L. : Glucosylation of low 
density lipoproteins to an extent соірагазіе to that seen in 
diabets slows their catabolisn. Diabetes 1984; 33: 130-4. 

8. Grote V D L - p a r t i k e l s (30-150 nm i n d iameter) worden evenals c h y l o ­
microns d i r e c t u i t de c i r c u l a t i e g e k l a a r d zonder o m z e t t i n g t o t LDL. 
Stalenhoef, A.F.H., telloy, M.J., Kane, J.P. and Kevel, 
R.J. : Ntetabolisn of gpolipoproteins B-48 and B-100 of t n -
glyceride-nch lipoproteins іл noimal and lipoprotein 
lipase-deficient hunais. Proc. Natl. Acad. Sci. USA 1984; 
81: 1839-43. 
9 . F y s i o t h e r a p i e b i j p r i m a i r e pneumonie h e e f t geen g u n s t i g e f f e c t op de 
g e n e z i n g . 
Britten, S., Bejstedt, M., and Vedm, L. : Chest physio­
therapy in primary рпеитюпіа. u-i t . ted.J. 1985; 290: 1703-4. 
10. Het invoeren van een algemeen c o - a s s i s t e n t s c h a p (ALCO) z a l de waarde 
van de daarop volgende k l i n i s c h e co-assistenschappen doen toenemen. 
1 1 . T i j d e n s de k l i n i s c h e co-ass istentschappen dienen t u s s e n t i j d s e e v a l u a ­
t i e s van e r v a r i n g en kundigheid van de student t e worden i n g e v o e r d . 
PMD projectgroep: Een evaluatie van het coschap interne 
geneeskinde 1984. 
12. De gewoonte om t e applaudiseren voor de p i l o o t na een geslaagde 
v l u c h t i s een u i t i n g van een gebrek aan vertrouwen i n de v e i l i g h e i d 
van het v l i e g v e r k e e r . 
Nijmegen, 12 september 1985 Fred Storms 



